drug1_db
stringlengths
7
7
drug2_db
stringlengths
7
7
drug1_id
int64
0
1.69k
drug2_id
int64
0
1.69k
drug_pair
listlengths
2
2
drug1_name
stringlengths
4
85
drug2_name
stringlengths
4
85
drug1_desc
stringlengths
27
1.09k
drug2_desc
stringlengths
27
6.14k
label
stringclasses
3 values
label_idx
int64
0
2
all_paths
listlengths
1
10
all_paths_str
listlengths
1
10
path_str
stringlengths
0
3.57k
DB00774
DB13928
1,577
1,385
[ "DDInter889", "DDInter1660" ]
Hydroflumethiazide
Semaglutide
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Moderate
1
[ [ [ 1577, 24, 1385 ] ], [ [ 1577, 1, 359 ], [ 359, 24, 1385 ] ], [ [ 1577, 24, 891 ], [ 891, 24, 1385 ] ], [ [ 1577, 63, 1144 ], [ 1144, 24, 1385 ] ], [ [ 1577, 40, 178 ], [ 178, 24, 1385 ] ], [ [ 1577, 1, 359 ], [ 359, 63, 891 ], [ 891, 24, 1385 ] ], [ [ 1577, 24, 891 ], [ 891, 40, 1103 ], [ 1103, 23, 1385 ] ], [ [ 1577, 63, 1144 ], [ 1144, 62, 1103 ], [ 1103, 23, 1385 ] ], [ [ 1577, 24, 1486 ], [ 1486, 64, 839 ], [ 839, 24, 1385 ] ], [ [ 1577, 24, 401 ], [ 401, 25, 1154 ], [ 1154, 24, 1385 ] ] ]
[ [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Chlorothiazide" ], [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Polythiazide" ], [ "Polythiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Chlorothiazide" ], [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ] ]
Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
DB01229
DB14568
973
982
[ "DDInter1378", "DDInter1000" ]
Paclitaxel (protein-bound)
Ivosidenib
Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Moderate
1
[ [ [ 973, 24, 982 ] ], [ [ 973, 63, 112 ], [ 112, 23, 982 ] ], [ [ 973, 25, 976 ], [ 976, 24, 982 ] ], [ [ 973, 63, 700 ], [ 700, 24, 982 ] ], [ [ 973, 64, 770 ], [ 770, 24, 982 ] ], [ [ 973, 24, 241 ], [ 241, 24, 982 ] ], [ [ 973, 24, 159 ], [ 159, 63, 982 ] ], [ [ 973, 62, 307 ], [ 307, 24, 982 ] ], [ [ 973, 24, 875 ], [ 875, 25, 982 ] ], [ [ 973, 63, 600 ], [ 600, 25, 982 ] ] ]
[ [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atorvastatin" ], [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erdafitinib" ], [ "Erdafitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Modafinil" ], [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fosaprepitant" ], [ "Fosaprepitant", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ] ]
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may lead to a major life threatening interaction when taken with Ivosidenib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
DB00046
DB00215
1,179
1,230
[ "DDInter940", "DDInter388" ]
Insulin lispro
Citalopram
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
Moderate
1
[ [ [ 1179, 24, 1230 ] ], [ [ 1179, 24, 318 ], [ 318, 40, 1230 ] ], [ [ 1179, 24, 168 ], [ 168, 23, 1230 ] ], [ [ 1179, 24, 590 ], [ 590, 63, 1230 ] ], [ [ 1179, 63, 521 ], [ 521, 25, 1230 ] ], [ [ 1179, 24, 820 ], [ 820, 64, 1230 ] ], [ [ 1179, 24, 73 ], [ 73, 25, 1230 ] ], [ [ 1179, 24, 318 ], [ 318, 6, 5744 ], [ 5744, 45, 1230 ] ], [ [ 1179, 24, 168 ], [ 168, 23, 318 ], [ 318, 40, 1230 ] ], [ [ 1179, 24, 590 ], [ 590, 24, 318 ], [ 318, 40, 1230 ] ] ]
[ [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} (Compound) resembles {v} (Compound)", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetohexamide" ], [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Goserelin" ], [ "Goserelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentermine" ], [ "Phentermine", "{u} may lead to a major life threatening interaction when taken with {v}", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} (Compound) binds {v} (Gene)", "HTR2C" ], [ "HTR2C", "{u} (Gene) is bound by {v} (Compound)", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} (Compound) resembles {v} (Compound)", "Citalopram" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetohexamide" ], [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} (Compound) resembles {v} (Compound)", "Citalopram" ] ] ]
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound) Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Citalopram Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Citalopram Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may lead to a major life threatening interaction when taken with Citalopram Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Citalopram Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) binds HTR2C (Gene) and HTR2C (Gene) is bound by Citalopram (Compound) Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound) Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
DB00580
DB00731
311
1,144
[ "DDInter1910", "DDInter1269" ]
Valdecoxib
Nateglinide
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Moderate
1
[ [ [ 311, 24, 1144 ] ], [ [ 311, 24, 1033 ], [ 1033, 63, 1144 ] ], [ [ 311, 63, 254 ], [ 254, 24, 1144 ] ], [ [ 311, 25, 629 ], [ 629, 63, 1144 ] ], [ [ 311, 24, 870 ], [ 870, 24, 1144 ] ], [ [ 311, 24, 1033 ], [ 1033, 63, 168 ], [ 168, 24, 1144 ] ], [ [ 311, 63, 254 ], [ 254, 21, 29222 ], [ 29222, 60, 1144 ] ], [ [ 311, 24, 50 ], [ 50, 6, 4789 ], [ 4789, 45, 1144 ] ], [ [ 311, 25, 629 ], [ 629, 63, 610 ], [ 610, 24, 1144 ] ], [ [ 311, 24, 609 ], [ 609, 24, 136 ], [ 136, 40, 1144 ] ] ]
[ [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nitisinone" ], [ "Nitisinone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nitisinone" ], [ "Nitisinone", "{u} (Compound) causes {v} (Side Effect)", "Hypoglycaemia" ], [ "Hypoglycaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfasalazine" ], [ "Sulfasalazine", "{u} (Compound) binds {v} (Gene)", "PPARG" ], [ "PPARG", "{u} (Gene) is bound by {v} (Compound)", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ] ], [ [ "Valdecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ], [ "Lacosamide", "{u} (Compound) resembles {v} (Compound)", "Nateglinide" ] ] ]
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Nateglinide (Compound) Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) binds PPARG (Gene) and PPARG (Gene) is bound by Nateglinide (Compound) Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide and Lacosamide (Compound) resembles Nateglinide (Compound)
DB00685
DB01073
1,299
1,488
[ "DDInter1887", "DDInter745" ]
Trovafloxacin
Fludarabine
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Minor
0
[ [ [ 1299, 23, 1488 ] ], [ [ 1299, 63, 372 ], [ 372, 1, 1488 ] ], [ [ 1299, 21, 28701 ], [ 28701, 60, 1488 ] ], [ [ 1299, 1, 1467 ], [ 1467, 23, 1488 ] ], [ [ 1299, 1, 872 ], [ 872, 62, 1488 ] ], [ [ 1299, 62, 134 ], [ 134, 24, 1488 ] ], [ [ 1299, 23, 995 ], [ 995, 24, 1488 ] ], [ [ 1299, 24, 384 ], [ 384, 63, 1488 ] ], [ [ 1299, 23, 37 ], [ 37, 63, 1488 ] ], [ [ 1299, 62, 1238 ], [ 1238, 25, 1488 ] ] ]
[ [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} (Compound) resembles {v} (Compound)", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} (Compound) causes {v} (Side Effect)", "Discomfort" ], [ "Discomfort", "{u} (Side Effect) is caused by {v} (Compound)", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Enoxacin" ], [ "Enoxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ], [ "Gemifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vinorelbine" ], [ "Vinorelbine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hydroxyurea" ], [ "Hydroxyurea", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lomustine" ], [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pentostatin" ], [ "Pentostatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fludarabine" ] ] ]
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound) Trovafloxacin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound) Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin and Pentostatin may lead to a major life threatening interaction when taken with Fludarabine
DB06697
DB09420
436
1,074
[ "DDInter121", "DDInter953" ]
Artemether
Iodide I-123
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.
Moderate
1
[ [ [ 436, 24, 1074 ] ], [ [ 436, 63, 1220 ], [ 1220, 24, 1074 ] ], [ [ 436, 63, 1220 ], [ 1220, 24, 1004 ], [ 1004, 63, 1074 ] ], [ [ 436, 63, 1243 ], [ 1243, 63, 126 ], [ 126, 24, 1074 ] ], [ [ 436, 63, 1249 ], [ 1249, 40, 339 ], [ 339, 24, 1074 ] ], [ [ 436, 5, 11571 ], [ 11571, 44, 161 ], [ 161, 24, 1074 ] ], [ [ 436, 63, 929 ], [ 929, 24, 161 ], [ 161, 24, 1074 ] ], [ [ 436, 63, 1220 ], [ 1220, 62, 523 ], [ 523, 24, 1074 ] ], [ [ 436, 63, 1249 ], [ 1249, 25, 126 ], [ 126, 24, 1074 ] ], [ [ 436, 6, 12523 ], [ 12523, 45, 272 ], [ 272, 24, 1074 ] ] ]
[ [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenyl salicylate" ], [ "Phenyl salicylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Proguanil" ], [ "Proguanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nafcillin" ], [ "Nafcillin", "{u} (Compound) resembles {v} (Compound)", "Bacampicillin" ], [ "Bacampicillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} (Compound) treats {v} (Disease)", "malaria" ], [ "malaria", "{u} (Disease) is treated by {v} (Compound)", "Sulfadiazine" ], [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pyrimethamine" ], [ "Pyrimethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfadiazine" ], [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Alprazolam" ], [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nafcillin" ], [ "Nafcillin", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Artemether", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ] ]
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Proguanil and Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin (Compound) resembles Bacampicillin (Compound) and Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether (Compound) treats malaria (Disease) and malaria (Disease) is treated by Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimethamine may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Alprazolam and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Artemether (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
DB00748
DB09118
662
1,580
[ "DDInter297", "DDInter1711" ]
Carbinoxamine
Stiripentol
Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Moderate
1
[ [ [ 662, 24, 1580 ] ], [ [ 662, 24, 1532 ], [ 1532, 24, 1580 ] ], [ [ 662, 24, 1609 ], [ 1609, 63, 1580 ] ], [ [ 662, 63, 1219 ], [ 1219, 24, 1580 ] ], [ [ 662, 35, 1376 ], [ 1376, 24, 1580 ] ], [ [ 662, 24, 1532 ], [ 1532, 63, 473 ], [ 473, 24, 1580 ] ], [ [ 662, 24, 1609 ], [ 1609, 63, 407 ], [ 407, 63, 1580 ] ], [ [ 662, 63, 1219 ], [ 1219, 24, 1532 ], [ 1532, 24, 1580 ] ], [ [ 662, 24, 1688 ], [ 1688, 24, 1609 ], [ 1609, 63, 1580 ] ], [ [ 662, 35, 1376 ], [ 1376, 24, 283 ], [ 283, 63, 1580 ] ] ]
[ [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenoxylate" ], [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ], [ [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ] ] ]
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
DB00738
DB00938
485
455
[ "DDInter1420", "DDInter1635" ]
Pentamidine
Salmeterol
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Moderate
1
[ [ [ 485, 24, 455 ] ], [ [ 485, 24, 688 ], [ 688, 63, 455 ] ], [ [ 485, 6, 8374 ], [ 8374, 45, 455 ] ], [ [ 485, 18, 9650 ], [ 9650, 46, 455 ] ], [ [ 485, 7, 7669 ], [ 7669, 46, 455 ] ], [ [ 485, 7, 6168 ], [ 6168, 57, 455 ] ], [ [ 485, 21, 29024 ], [ 29024, 60, 455 ] ], [ [ 485, 25, 1568 ], [ 1568, 63, 455 ] ], [ [ 485, 63, 1262 ], [ 1262, 24, 455 ] ], [ [ 485, 24, 1490 ], [ 1490, 24, 455 ] ] ]
[ [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Pentamidine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Salmeterol" ] ], [ [ "Pentamidine", "{u} (Compound) downregulates {v} (Gene)", "HMGCS1" ], [ "HMGCS1", "{u} (Gene) is upregulated by {v} (Compound)", "Salmeterol" ] ], [ [ "Pentamidine", "{u} (Compound) upregulates {v} (Gene)", "DDIT4" ], [ "DDIT4", "{u} (Gene) is upregulated by {v} (Compound)", "Salmeterol" ] ], [ [ "Pentamidine", "{u} (Compound) upregulates {v} (Gene)", "IGFBP3" ], [ "IGFBP3", "{u} (Gene) is downregulated by {v} (Compound)", "Salmeterol" ] ], [ [ "Pentamidine", "{u} (Compound) causes {v} (Side Effect)", "Hypertension" ], [ "Hypertension", "{u} (Side Effect) is caused by {v} (Compound)", "Salmeterol" ] ], [ [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Pimozide" ], [ "Pimozide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perflutren" ], [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofazimine" ], [ "Clofazimine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ] ]
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol Pentamidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound) Pentamidine (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Salmeterol (Compound) Pentamidine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Salmeterol (Compound) Pentamidine (Compound) upregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Salmeterol (Compound) Pentamidine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Salmeterol (Compound) Pentamidine may lead to a major life threatening interaction when taken with Pimozide and Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine and Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
DB00046
DB00816
1,179
1,674
[ "DDInter940", "DDInter1346" ]
Insulin lispro
Orciprenaline
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Moderate
1
[ [ [ 1179, 24, 1674 ] ], [ [ 1179, 24, 874 ], [ 874, 24, 1674 ] ], [ [ 1179, 24, 251 ], [ 251, 23, 1674 ] ], [ [ 1179, 24, 891 ], [ 891, 62, 1674 ] ], [ [ 1179, 24, 819 ], [ 819, 63, 1674 ] ], [ [ 1179, 25, 739 ], [ 739, 63, 1674 ] ], [ [ 1179, 63, 521 ], [ 521, 24, 1674 ] ], [ [ 1179, 25, 839 ], [ 839, 25, 1674 ] ], [ [ 1179, 24, 699 ], [ 699, 64, 1674 ] ], [ [ 1179, 24, 461 ], [ 461, 25, 1674 ] ] ]
[ [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epinephrine" ], [ "Epinephrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acebutolol" ], [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may lead to a major life threatening interaction when taken with {v}", "Lomefloxacin" ], [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Goserelin" ], [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nadolol" ], [ "Nadolol", "{u} may lead to a major life threatening interaction when taken with {v}", "Orciprenaline" ] ], [ [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Timolol" ], [ "Timolol", "{u} may lead to a major life threatening interaction when taken with {v}", "Orciprenaline" ] ] ]
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Insulin lispro may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Insulin lispro may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may lead to a major life threatening interaction when taken with Orciprenaline Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may lead to a major life threatening interaction when taken with Orciprenaline
DB00930
DB06410
166
1,196
[ "DDInter432", "DDInter595" ]
Colesevelam
Doxercalciferol
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.
Moderate
1
[ [ [ 166, 24, 1196 ] ], [ [ 166, 63, 1331 ], [ 1331, 25, 1196 ] ], [ [ 166, 24, 1098 ], [ 1098, 25, 1196 ] ], [ [ 166, 63, 1331 ], [ 1331, 23, 1142 ], [ 1142, 23, 1196 ] ], [ [ 166, 24, 1098 ], [ 1098, 23, 1142 ], [ 1142, 23, 1196 ] ], [ [ 166, 63, 1041 ], [ 1041, 63, 359 ], [ 359, 24, 1196 ] ], [ [ 166, 24, 959 ], [ 959, 63, 417 ], [ 417, 25, 1196 ] ], [ [ 166, 63, 1331 ], [ 1331, 24, 359 ], [ 359, 24, 1196 ] ], [ [ 166, 24, 1098 ], [ 1098, 63, 359 ], [ 359, 24, 1196 ] ], [ [ 166, 24, 959 ], [ 959, 24, 1142 ], [ 1142, 23, 1196 ] ] ]
[ [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ergocalciferol" ], [ "Ergocalciferol", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dihydrotachysterol" ], [ "Dihydrotachysterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ergocalciferol" ], [ "Ergocalciferol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orlistat" ], [ "Orlistat", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dihydrotachysterol" ], [ "Dihydrotachysterol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orlistat" ], [ "Orlistat", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paricalcitol" ], [ "Paricalcitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorothiazide" ], [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sucralfate" ], [ "Sucralfate", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ergocalciferol" ], [ "Ergocalciferol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorothiazide" ], [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dihydrotachysterol" ], [ "Dihydrotachysterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorothiazide" ], [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxercalciferol" ] ], [ [ "Colesevelam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orlistat" ], [ "Orlistat", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doxercalciferol" ] ] ]
Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may lead to a major life threatening interaction when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may lead to a major life threatening interaction when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may lead to a major life threatening interaction when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol
DB00015
DB01105
582
222
[ "DDInter1585", "DDInter1665" ]
Reteplase
Sibutramine
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Moderate
1
[ [ [ 582, 24, 222 ] ], [ [ 582, 25, 802 ], [ 802, 63, 222 ] ], [ [ 582, 24, 1027 ], [ 1027, 24, 222 ] ], [ [ 582, 25, 1432 ], [ 1432, 24, 222 ] ], [ [ 582, 24, 958 ], [ 958, 63, 222 ] ], [ [ 582, 64, 942 ], [ 942, 24, 222 ] ], [ [ 582, 24, 1039 ], [ 1039, 64, 222 ] ], [ [ 582, 24, 529 ], [ 529, 25, 222 ] ], [ [ 582, 25, 802 ], [ 802, 64, 1046 ], [ 1046, 63, 222 ] ], [ [ 582, 25, 1046 ], [ 1046, 25, 802 ], [ 802, 63, 222 ] ] ]
[ [ [ "Reteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Tinzaparin" ], [ "Tinzaparin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ], [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Abciximab" ], [ "Abciximab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ], [ "Ginkgo biloba", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Tinzaparin" ], [ "Tinzaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ], [ [ "Reteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Tinzaparin" ], [ "Tinzaparin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ] ] ]
Reteplase may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba and Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may lead to a major life threatening interaction when taken with Sibutramine Reteplase may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine Reteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
DB08860
DB08912
788
1,040
[ "DDInter1479", "DDInter462" ]
Pitavastatin
Dabrafenib
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Moderate
1
[ [ [ 788, 24, 1040 ] ], [ [ 788, 6, 13478 ], [ 13478, 45, 1040 ] ], [ [ 788, 7, 2969 ], [ 2969, 46, 1040 ] ], [ [ 788, 18, 10351 ], [ 10351, 46, 1040 ] ], [ [ 788, 18, 7335 ], [ 7335, 57, 1040 ] ], [ [ 788, 7, 2186 ], [ 2186, 57, 1040 ] ], [ [ 788, 21, 28900 ], [ 28900, 60, 1040 ] ], [ [ 788, 63, 168 ], [ 168, 23, 1040 ] ], [ [ 788, 24, 466 ], [ 466, 63, 1040 ] ], [ [ 788, 62, 126 ], [ 126, 24, 1040 ] ] ]
[ [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) binds {v} (Gene)", "SLCO1B3" ], [ "SLCO1B3", "{u} (Gene) is bound by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) upregulates {v} (Gene)", "CDKN1A" ], [ "CDKN1A", "{u} (Gene) is upregulated by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) downregulates {v} (Gene)", "ATF6" ], [ "ATF6", "{u} (Gene) is upregulated by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) downregulates {v} (Gene)", "LIG1" ], [ "LIG1", "{u} (Gene) is downregulated by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) upregulates {v} (Gene)", "HSPA1A" ], [ "HSPA1A", "{u} (Gene) is downregulated by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} (Compound) causes {v} (Side Effect)", "Abdominal pain" ], [ "Abdominal pain", "{u} (Side Effect) is caused by {v} (Compound)", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ] ], [ [ "Pitavastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ] ] ]
Pitavastatin (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound) Pitavastatin (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound) Pitavastatin (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Dabrafenib (Compound) Pitavastatin (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is downregulated by Dabrafenib (Compound) Pitavastatin (Compound) upregulates HSPA1A (Gene) and HSPA1A (Gene) is downregulated by Dabrafenib (Compound) Pitavastatin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound) Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib Pitavastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
DB01238
DB09082
673
659
[ "DDInter118", "DDInter1934" ]
Aripiprazole
Vilanterol
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Moderate
1
[ [ [ 673, 24, 659 ] ], [ [ 673, 63, 1220 ], [ 1220, 23, 659 ] ], [ [ 673, 24, 1296 ], [ 1296, 63, 659 ] ], [ [ 673, 24, 1069 ], [ 1069, 24, 659 ] ], [ [ 673, 63, 222 ], [ 222, 24, 659 ] ], [ [ 673, 1, 827 ], [ 827, 24, 659 ] ], [ [ 673, 74, 477 ], [ 477, 24, 659 ] ], [ [ 673, 40, 1630 ], [ 1630, 24, 659 ] ], [ [ 673, 24, 877 ], [ 877, 64, 659 ] ], [ [ 673, 63, 1220 ], [ 1220, 1, 891 ], [ 891, 23, 659 ] ] ]
[ [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vandetanib" ], [ "Vandetanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} (Compound) resembles {v} (Compound)", "Trazodone" ], [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cilostazol" ], [ "Cilostazol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ], [ "Perphenazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Vilanterol" ] ], [ [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} (Compound) resembles {v} (Compound)", "Prednisolone" ], [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ] ] ]
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole (Compound) resembles Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole (Compound) resembles Cilostazol (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
DB00284
DB06788
1,647
1,616
[ "DDInter11", "DDInter864" ]
Acarbose
Histrelin
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).
Moderate
1
[ [ [ 1647, 24, 1616 ] ], [ [ 1647, 24, 1664 ], [ 1664, 24, 1616 ] ], [ [ 1647, 23, 135 ], [ 135, 63, 1616 ] ], [ [ 1647, 24, 659 ], [ 659, 63, 1616 ] ], [ [ 1647, 1, 355 ], [ 355, 24, 1616 ] ], [ [ 1647, 23, 1645 ], [ 1645, 24, 1616 ] ], [ [ 1647, 24, 684 ], [ 684, 25, 1616 ] ], [ [ 1647, 24, 996 ], [ 996, 64, 1616 ] ], [ [ 1647, 25, 246 ], [ 246, 25, 1616 ] ], [ [ 1647, 63, 1176 ], [ 1176, 25, 1616 ] ] ]
[ [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Risperidone" ], [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Albiglutide" ], [ "Albiglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} (Compound) resembles {v} (Compound)", "Lactulose" ], [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metformin" ], [ "Metformin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thioridazine" ], [ "Thioridazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bedaquiline" ], [ "Bedaquiline", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may lead to a major life threatening interaction when taken with {v}", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Moxifloxacin" ], [ "Moxifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ] ]
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Acarbose (Compound) resembles Lactulose (Compound) and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Histrelin Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Histrelin Acarbose may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Histrelin Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Histrelin
DB01284
DB09082
1,042
659
[ "DDInter1782", "DDInter1934" ]
Tetracosactide
Vilanterol
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Minor
0
[ [ [ 1042, 23, 659 ] ], [ [ 1042, 24, 1296 ], [ 1296, 63, 659 ] ], [ [ 1042, 63, 88 ], [ 88, 24, 659 ] ], [ [ 1042, 24, 1450 ], [ 1450, 24, 659 ] ], [ [ 1042, 62, 1674 ], [ 1674, 24, 659 ] ], [ [ 1042, 23, 1032 ], [ 1032, 63, 659 ] ], [ [ 1042, 64, 932 ], [ 932, 24, 659 ] ], [ [ 1042, 25, 1011 ], [ 1011, 24, 659 ] ], [ [ 1042, 24, 877 ], [ 877, 64, 659 ] ], [ [ 1042, 63, 772 ], [ 772, 25, 659 ] ] ]
[ [ [ "Tetracosactide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoprolol" ], [ "Metoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ], [ "Empagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levosalbutamol" ], [ "Levosalbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mifepristone" ], [ "Mifepristone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Vilanterol" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ], [ "Carvedilol", "{u} may lead to a major life threatening interaction when taken with {v}", "Vilanterol" ] ] ]
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol
DB01076
DB12332
700
1,619
[ "DDInter133", "DDInter1626" ]
Atorvastatin
Rucaparib
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
Moderate
1
[ [ [ 700, 24, 1619 ] ], [ [ 700, 63, 112 ], [ 112, 23, 1619 ] ], [ [ 700, 24, 259 ], [ 259, 24, 1619 ] ], [ [ 700, 63, 1419 ], [ 1419, 24, 1619 ] ], [ [ 700, 24, 1501 ], [ 1501, 63, 1619 ] ], [ [ 700, 25, 609 ], [ 609, 24, 1619 ] ], [ [ 700, 40, 1080 ], [ 1080, 24, 1619 ] ], [ [ 700, 23, 578 ], [ 578, 24, 1619 ] ], [ [ 700, 64, 600 ], [ 600, 24, 1619 ] ], [ [ 700, 62, 126 ], [ 126, 24, 1619 ] ] ]
[ [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilonacept" ], [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enasidenib" ], [ "Enasidenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} (Compound) resembles {v} (Compound)", "Conivaptan" ], [ "Conivaptan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ], [ [ "Atorvastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ] ] ]
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin (Compound) resembles Conivaptan (Compound) and Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
DB00222
DB00726
245
1,164
[ "DDInter825", "DDInter1876" ]
Glimepiride
Trimipramine
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Moderate
1
[ [ [ 245, 24, 1164 ] ], [ [ 245, 24, 1237 ], [ 1237, 40, 1164 ] ], [ [ 245, 6, 6017 ], [ 6017, 45, 1164 ] ], [ [ 245, 21, 28809 ], [ 28809, 60, 1164 ] ], [ [ 245, 24, 1674 ], [ 1674, 63, 1164 ] ], [ [ 245, 24, 999 ], [ 999, 24, 1164 ] ], [ [ 245, 40, 1411 ], [ 1411, 63, 1164 ] ], [ [ 245, 63, 521 ], [ 521, 24, 1164 ] ], [ [ 245, 64, 600 ], [ 600, 24, 1164 ] ], [ [ 245, 24, 22 ], [ 22, 64, 1164 ] ] ]
[ [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clomipramine" ], [ "Clomipramine", "{u} (Compound) resembles {v} (Compound)", "Trimipramine" ] ], [ [ "Glimepiride", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Trimipramine" ] ], [ [ "Glimepiride", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Goserelin" ], [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ephedrine" ], [ "Ephedrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Trimipramine" ] ] ]
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound) Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trimipramine (Compound) Glimepiride (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Trimipramine (Compound) Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may lead to a major life threatening interaction when taken with Trimipramine
DB00631
DB08904
372
375
[ "DDInter405", "DDInter342" ]
Clofarabine
Certolizumab pegol
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Major
2
[ [ [ 372, 25, 375 ] ], [ [ 372, 63, 1461 ], [ 1461, 23, 375 ] ], [ [ 372, 24, 231 ], [ 231, 24, 375 ] ], [ [ 372, 24, 200 ], [ 200, 63, 375 ] ], [ [ 372, 63, 66 ], [ 66, 24, 375 ] ], [ [ 372, 64, 1066 ], [ 1066, 25, 375 ] ], [ [ 372, 63, 552 ], [ 552, 25, 375 ] ], [ [ 372, 24, 328 ], [ 328, 25, 375 ] ], [ [ 372, 24, 1330 ], [ 1330, 64, 375 ] ], [ [ 372, 25, 1624 ], [ 1624, 64, 375 ] ] ]
[ [ [ "Clofarabine", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stavudine" ], [ "Stavudine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ], [ "Candida albicans", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Efalizumab" ], [ "Efalizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mercaptopurine" ], [ "Mercaptopurine", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naxitamab" ], [ "Naxitamab", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ], [ [ "Clofarabine", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ], [ "Rotavirus vaccine", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ] ] ]
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol Clofarabine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may lead to a major life threatening interaction when taken with Certolizumab pegol Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol Clofarabine may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol
DB00398
DB09046
79
1,094
[ "DDInter1702", "DDInter1201" ]
Sorafenib
Metreleptin
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus. In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.
Moderate
1
[ [ [ 79, 24, 1094 ] ], [ [ 79, 24, 230 ], [ 230, 62, 1094 ] ], [ [ 79, 23, 1135 ], [ 1135, 63, 1094 ] ], [ [ 79, 24, 180 ], [ 180, 63, 1094 ] ], [ [ 79, 24, 578 ], [ 578, 24, 1094 ] ], [ [ 79, 25, 39 ], [ 39, 24, 1094 ] ], [ [ 79, 64, 576 ], [ 576, 24, 1094 ] ], [ [ 79, 25, 985 ], [ 985, 63, 1094 ] ], [ [ 79, 24, 879 ], [ 879, 25, 1094 ] ], [ [ 79, 24, 230 ], [ 230, 64, 578 ], [ 578, 24, 1094 ] ] ]
[ [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Relugolix" ], [ "Relugolix", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oliceridine" ], [ "Oliceridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ], [ "Panobinostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Methadone" ], [ "Methadone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lumateperone" ], [ "Lumateperone", "{u} may lead to a major life threatening interaction when taken with {v}", "Metreleptin" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Relugolix" ], [ "Relugolix", "{u} may lead to a major life threatening interaction when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metreleptin" ] ] ]
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix and Relugolix may cause a minor interaction that can limit clinical effects when taken with Metreleptin Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone and Lumateperone may lead to a major life threatening interaction when taken with Metreleptin Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix and Relugolix may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
DB00377
DB12141
1,494
971
[ "DDInter1382", "DDInter817" ]
Palonosetron
Gilteritinib
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Moderate
1
[ [ [ 1494, 24, 971 ] ], [ [ 1494, 23, 1247 ], [ 1247, 23, 971 ] ], [ [ 1494, 24, 485 ], [ 485, 24, 971 ] ], [ [ 1494, 25, 1097 ], [ 1097, 24, 971 ] ], [ [ 1494, 24, 730 ], [ 730, 63, 971 ] ], [ [ 1494, 64, 1100 ], [ 1100, 24, 971 ] ], [ [ 1494, 63, 1181 ], [ 1181, 24, 971 ] ], [ [ 1494, 25, 180 ], [ 180, 63, 971 ] ], [ [ 1494, 25, 540 ], [ 540, 25, 971 ] ], [ [ 1494, 64, 228 ], [ 228, 25, 971 ] ] ]
[ [ [ "Palonosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Lasmiditan" ], [ "Lasmiditan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ], [ "Deutetrabenazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Venlafaxine" ], [ "Venlafaxine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Oliceridine" ], [ "Oliceridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Dronedarone" ], [ "Dronedarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ], [ [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Dofetilide" ], [ "Dofetilide", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ] ]
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may lead to a major life threatening interaction when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Palonosetron may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib Palonosetron may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may lead to a major life threatening interaction when taken with Gilteritinib
DB00635
DB00661
1,573
122
[ "DDInter1515", "DDInter1928" ]
Prednisone
Verapamil
A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955.
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.
Moderate
1
[ [ [ 1573, 24, 122 ] ], [ [ 1573, 10, 11610 ], [ 11610, 44, 122 ] ], [ [ 1573, 6, 6648 ], [ 6648, 45, 122 ] ], [ [ 1573, 21, 28809 ], [ 28809, 60, 122 ] ], [ [ 1573, 63, 1101 ], [ 1101, 23, 122 ] ], [ [ 1573, 24, 283 ], [ 283, 62, 122 ] ], [ [ 1573, 24, 723 ], [ 723, 63, 122 ] ], [ [ 1573, 63, 1031 ], [ 1031, 24, 122 ] ], [ [ 1573, 25, 770 ], [ 770, 63, 122 ] ], [ [ 1573, 1, 617 ], [ 617, 63, 122 ] ] ]
[ [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} (Compound) palliates {v} (Disease)", "migraine" ], [ "migraine", "{u} (Disease) is treated by {v} (Compound)", "Verapamil" ] ], [ [ "Prednisone", "{u} (Compound) binds {v} (Gene)", "SLCO1A2" ], [ "SLCO1A2", "{u} (Gene) is bound by {v} (Compound)", "Verapamil" ] ], [ [ "Prednisone", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Verapamil" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ] ], [ [ "Prednisone", "{u} (Compound) resembles {v} (Compound)", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ] ] ]
Prednisone (Compound) palliates migraine (Disease) and migraine (Disease) is treated by Verapamil (Compound) Prednisone (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Verapamil (Compound) Prednisone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound) Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Verapamil Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Verapamil Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Verapamil Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Verapamil Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Verapamil Prednisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
DB00321
DB11837
21
1,297
[ "DDInter78", "DDInter1351" ]
Amitriptyline
Osilodrostat
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.
Moderate
1
[ [ [ 21, 24, 1297 ] ], [ [ 21, 23, 112 ], [ 112, 23, 1297 ] ], [ [ 21, 25, 222 ], [ 222, 23, 1297 ] ], [ [ 21, 35, 401 ], [ 401, 24, 1297 ] ], [ [ 21, 24, 1555 ], [ 1555, 24, 1297 ] ], [ [ 21, 1, 508 ], [ 508, 24, 1297 ] ], [ [ 21, 24, 971 ], [ 971, 63, 1297 ] ], [ [ 21, 25, 1133 ], [ 1133, 24, 1297 ] ], [ [ 21, 63, 600 ], [ 600, 24, 1297 ] ], [ [ 21, 40, 1164 ], [ 1164, 24, 1297 ] ] ]
[ [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ], [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound)", "Promazine" ], [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Granisetron" ], [ "Granisetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound)", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ] ]
Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Amitriptyline may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Amitriptyline (Compound) resembles Promethazine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
DB01267
DB04868
519
478
[ "DDInter1381", "DDInter1293" ]
Paliperidone
Nilotinib
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Major
2
[ [ [ 519, 25, 478 ] ], [ [ 519, 6, 8374 ], [ 8374, 45, 478 ] ], [ [ 519, 21, 31778 ], [ 31778, 60, 478 ] ], [ [ 519, 62, 112 ], [ 112, 23, 478 ] ], [ [ 519, 63, 1559 ], [ 1559, 24, 478 ] ], [ [ 519, 24, 761 ], [ 761, 63, 478 ] ], [ [ 519, 64, 593 ], [ 593, 24, 478 ] ], [ [ 519, 25, 868 ], [ 868, 64, 478 ] ], [ [ 519, 63, 1424 ], [ 1424, 25, 478 ] ], [ [ 519, 24, 1228 ], [ 1228, 64, 478 ] ] ]
[ [ [ "Paliperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Nilotinib" ] ], [ [ "Paliperidone", "{u} (Compound) causes {v} (Side Effect)", "Bundle branch block left" ], [ "Bundle branch block left", "{u} (Side Effect) is caused by {v} (Compound)", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Famotidine" ], [ "Famotidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ] ], [ [ "Paliperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ], [ "Lenvatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ] ] ]
Paliperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound) Paliperidone (Compound) causes Bundle branch block left (Side Effect) and Bundle branch block left (Side Effect) is caused by Nilotinib (Compound) Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib Paliperidone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib Paliperidone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Nilotinib Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Nilotinib Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may lead to a major life threatening interaction when taken with Nilotinib
DB00358
DB01072
1,010
915
[ "DDInter1140", "DDInter129" ]
Mefloquine
Atazanavir
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Major
2
[ [ [ 1010, 25, 915 ] ], [ [ 1010, 24, 833 ], [ 833, 1, 915 ] ], [ [ 1010, 25, 1327 ], [ 1327, 1, 915 ] ], [ [ 1010, 6, 4973 ], [ 4973, 45, 915 ] ], [ [ 1010, 21, 29052 ], [ 29052, 60, 915 ] ], [ [ 1010, 24, 1374 ], [ 1374, 62, 915 ] ], [ [ 1010, 63, 1101 ], [ 1101, 24, 915 ] ], [ [ 1010, 24, 129 ], [ 129, 63, 915 ] ], [ [ 1010, 25, 1011 ], [ 1011, 63, 915 ] ], [ [ 1010, 24, 1424 ], [ 1424, 24, 915 ] ] ]
[ [ [ "Mefloquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lopinavir" ], [ "Lopinavir", "{u} (Compound) resembles {v} (Compound)", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Saquinavir" ], [ "Saquinavir", "{u} (Compound) resembles {v} (Compound)", "Atazanavir" ] ], [ [ "Mefloquine", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Atazanavir" ] ], [ [ "Mefloquine", "{u} (Compound) causes {v} (Side Effect)", "Sleep disorder" ], [ "Sleep disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abiraterone" ], [ "Abiraterone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ] ]
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Atazanavir (Compound) Mefloquine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound) Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound) Mefloquine (Compound) causes Sleep disorder (Side Effect) and Sleep disorder (Side Effect) is caused by Atazanavir (Compound) Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Atazanavir Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Mefloquine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
DB00888
DB04865
1,001
4
[ "DDInter1133", "DDInter1335" ]
Mechlorethamine
Omacetaxine mepesuccinate
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Moderate
1
[ [ [ 1001, 24, 4 ] ], [ [ 1001, 25, 770 ], [ 770, 24, 4 ] ], [ [ 1001, 24, 496 ], [ 496, 63, 4 ] ], [ [ 1001, 63, 66 ], [ 66, 24, 4 ] ], [ [ 1001, 24, 1532 ], [ 1532, 24, 4 ] ], [ [ 1001, 40, 450 ], [ 450, 24, 4 ] ], [ [ 1001, 25, 1292 ], [ 1292, 64, 4 ] ], [ [ 1001, 62, 126 ], [ 126, 25, 4 ] ], [ [ 1001, 64, 1066 ], [ 1066, 25, 4 ] ], [ [ 1001, 25, 1377 ], [ 1377, 25, 4 ] ] ]
[ [ [ "Mechlorethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hepatitis A Vaccine" ], [ "Hepatitis A Vaccine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Efalizumab" ], [ "Efalizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} (Compound) resembles {v} (Compound)", "Cyclophosphamide" ], [ "Cyclophosphamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Mechlorethamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ] ]
Mechlorethamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Mechlorethamine may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Mechlorethamine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
DB01242
DB06704
1,237
247
[ "DDInter410", "DDInter952" ]
Clomipramine
Iobenguane (I-131)
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound.
Major
2
[ [ [ 1237, 37, 247 ] ], [ [ 1237, 6, 7390 ], [ 7390, 45, 247 ] ], [ [ 1237, 21, 28787 ], [ 28787, 60, 247 ] ], [ [ 1237, 24, 820 ], [ 820, 24, 247 ] ], [ [ 1237, 40, 1178 ], [ 1178, 24, 247 ] ], [ [ 1237, 1, 146 ], [ 146, 24, 247 ] ], [ [ 1237, 63, 999 ], [ 999, 24, 247 ] ], [ [ 1237, 25, 1629 ], [ 1629, 64, 247 ] ], [ [ 1237, 25, 497 ], [ 497, 25, 247 ] ], [ [ 1237, 24, 31 ], [ 31, 25, 247 ] ] ]
[ [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} (Compound) binds {v} (Gene)", "SLC6A2" ], [ "SLC6A2", "{u} (Gene) is bound by {v} (Compound)", "Iobenguane" ] ], [ [ "Clomipramine", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Iobenguane" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} (Compound) resembles {v} (Compound)", "Trifluoperazine" ], [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} (Compound) resembles {v} (Compound)", "Propiomazine" ], [ "Propiomazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Methylene blue" ], [ "Methylene blue", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ], [ "Iohexol", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Xylometazoline" ], [ "Xylometazoline", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ] ]
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Clomipramine may lead to a major life threatening interaction when taken with Iobenguane Clomipramine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound) Clomipramine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound) Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Clomipramine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Clomipramine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Clomipramine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane Clomipramine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Iobenguane Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline and Xylometazoline may lead to a major life threatening interaction when taken with Iobenguane
DB00087
DB05273
599
507
[ "DDInter41", "DDInter1638" ]
Alemtuzumab
Samarium (153Sm) lexidronam
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Major
2
[ [ [ 599, 25, 507 ] ], [ [ 599, 24, 248 ], [ 248, 24, 507 ] ], [ [ 599, 24, 270 ], [ 270, 63, 507 ] ], [ [ 599, 24, 196 ], [ 196, 25, 507 ] ], [ [ 599, 24, 110 ], [ 110, 64, 507 ] ], [ [ 599, 63, 491 ], [ 491, 25, 507 ] ], [ [ 599, 25, 1064 ], [ 1064, 25, 507 ] ], [ [ 599, 25, 1259 ], [ 1259, 64, 507 ] ], [ [ 599, 24, 248 ], [ 248, 40, 563 ], [ 563, 24, 507 ] ], [ [ 599, 24, 563 ], [ 563, 1, 248 ], [ 248, 24, 507 ] ] ]
[ [ [ "Alemtuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Valganciclovir" ], [ "Valganciclovir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Altretamine" ], [ "Altretamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ], [ "Polatuzumab vedotin", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Valganciclovir" ], [ "Valganciclovir", "{u} (Compound) resembles {v} (Compound)", "Ganciclovir" ], [ "Ganciclovir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Samarium (153Sm) lexidronam" ] ], [ [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ganciclovir" ], [ "Ganciclovir", "{u} (Compound) resembles {v} (Compound)", "Valganciclovir" ], [ "Valganciclovir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Samarium (153Sm) lexidronam" ] ] ]
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam Alemtuzumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
DB01182
DB11113
371
657
[ "DDInter1534", "DDInter307" ]
Propafenone
Castor oil
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products.
Moderate
1
[ [ [ 371, 24, 657 ] ], [ [ 371, 24, 927 ], [ 927, 63, 657 ] ], [ [ 371, 24, 1491 ], [ 1491, 24, 657 ] ], [ [ 371, 25, 985 ], [ 985, 24, 657 ] ], [ [ 371, 63, 1181 ], [ 1181, 24, 657 ] ], [ [ 371, 25, 351 ], [ 351, 63, 657 ] ], [ [ 371, 40, 847 ], [ 847, 24, 657 ] ], [ [ 371, 64, 57 ], [ 57, 24, 657 ] ], [ [ 371, 1, 675 ], [ 675, 24, 657 ] ], [ [ 371, 24, 927 ], [ 927, 63, 1079 ], [ 1079, 24, 657 ] ] ]
[ [ [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} (Compound) resembles {v} (Compound)", "Atomoxetine" ], [ "Atomoxetine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may lead to a major life threatening interaction when taken with {v}", "Arsenic trioxide" ], [ "Arsenic trioxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} (Compound) resembles {v} (Compound)", "Dextropropoxyphene" ], [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telavancin" ], [ "Telavancin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ] ]
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
DB06228
DB08820
792
1,478
[ "DDInter1609", "DDInter997" ]
Rivaroxaban
Ivacaftor
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Moderate
1
[ [ [ 792, 24, 1478 ] ], [ [ 792, 6, 8374 ], [ 8374, 45, 1478 ] ], [ [ 792, 21, 29221 ], [ 29221, 60, 1478 ] ], [ [ 792, 62, 307 ], [ 307, 23, 1478 ] ], [ [ 792, 63, 318 ], [ 318, 23, 1478 ] ], [ [ 792, 25, 1650 ], [ 1650, 63, 1478 ] ], [ [ 792, 63, 762 ], [ 762, 24, 1478 ] ], [ [ 792, 24, 1040 ], [ 1040, 63, 1478 ] ], [ [ 792, 64, 804 ], [ 804, 24, 1478 ] ], [ [ 792, 25, 39 ], [ 39, 24, 1478 ] ] ]
[ [ [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} (Compound) causes {v} (Side Effect)", "Infestation" ], [ "Infestation", "{u} (Side Effect) is caused by {v} (Compound)", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Modafinil" ], [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Avapritinib" ], [ "Avapritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bepridil" ], [ "Bepridil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Sulfinpyrazone" ], [ "Sulfinpyrazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Rivaroxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ], [ "Panobinostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ] ]
Rivaroxaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) Rivaroxaban (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound) Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor Rivaroxaban may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Rivaroxaban may lead to a major life threatening interaction when taken with Sulfinpyrazone and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Rivaroxaban may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
DB05239
DB10276
866
1,624
[ "DDInter425", "DDInter1623" ]
Cobimetinib
Rotavirus vaccine
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
Major
2
[ [ [ 866, 25, 1624 ] ], [ [ 866, 63, 322 ], [ 322, 25, 1624 ] ], [ [ 866, 25, 375 ], [ 375, 25, 1624 ] ], [ [ 866, 64, 1220 ], [ 1220, 25, 1624 ] ], [ [ 866, 24, 270 ], [ 270, 64, 1624 ] ], [ [ 866, 24, 850 ], [ 850, 25, 1624 ] ], [ [ 866, 25, 1259 ], [ 1259, 64, 1624 ] ], [ [ 866, 63, 322 ], [ 322, 63, 552 ], [ 552, 25, 1624 ] ], [ [ 866, 25, 375 ], [ 375, 64, 617 ], [ 617, 24, 1624 ] ], [ [ 866, 63, 58 ], [ 58, 24, 617 ], [ 617, 24, 1624 ] ] ]
[ [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may lead to a major life threatening interaction when taken with {v}", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rotavirus vaccine" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alefacept" ], [ "Alefacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rotavirus vaccine" ] ] ]
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine Cobimetinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
DB00581
DB01234
355
1,220
[ "DDInter1018", "DDInter513" ]
Lactulose
Dexamethasone
Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Moderate
1
[ [ [ 355, 24, 1220 ] ], [ [ 355, 24, 870 ], [ 870, 1, 1220 ] ], [ [ 355, 24, 175 ], [ 175, 40, 1220 ] ], [ [ 355, 63, 251 ], [ 251, 1, 1220 ] ], [ [ 355, 21, 28709 ], [ 28709, 60, 1220 ] ], [ [ 355, 23, 1117 ], [ 1117, 62, 1220 ] ], [ [ 355, 24, 688 ], [ 688, 23, 1220 ] ], [ [ 355, 24, 1612 ], [ 1612, 62, 1220 ] ], [ [ 355, 63, 228 ], [ 228, 23, 1220 ] ], [ [ 355, 24, 1056 ], [ 1056, 24, 1220 ] ] ]
[ [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludrocortisone" ], [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Lactulose", "{u} (Compound) causes {v} (Side Effect)", "Decreased appetite" ], [ "Decreased appetite", "{u} (Side Effect) is caused by {v} (Compound)", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sodium bicarbonate" ], [ "Sodium bicarbonate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostemsavir" ], [ "Fostemsavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dofetilide" ], [ "Dofetilide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telithromycin" ], [ "Telithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ] ] ]
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound) Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound) Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Dexamethasone (Compound) Lactulose (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Dexamethasone (Compound) Lactulose may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
DB00434
DB00780
13
551
[ "DDInter459", "DDInter1440" ]
Cyproheptadine
Phenelzine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Moderate
1
[ [ [ 13, 24, 551 ] ], [ [ 13, 24, 94 ], [ 94, 40, 551 ] ], [ [ 13, 7, 13230 ], [ 13230, 46, 551 ] ], [ [ 13, 7, 8368 ], [ 8368, 57, 551 ] ], [ [ 13, 21, 28722 ], [ 28722, 60, 551 ] ], [ [ 13, 24, 1442 ], [ 1442, 23, 551 ] ], [ [ 13, 24, 1192 ], [ 1192, 62, 551 ] ], [ [ 13, 63, 19 ], [ 19, 23, 551 ] ], [ [ 13, 63, 999 ], [ 999, 24, 551 ] ], [ [ 13, 24, 537 ], [ 537, 63, 551 ] ] ]
[ [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenacemide" ], [ "Phenacemide", "{u} (Compound) resembles {v} (Compound)", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} (Compound) upregulates {v} (Gene)", "TIPARP" ], [ "TIPARP", "{u} (Gene) is upregulated by {v} (Compound)", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} (Compound) upregulates {v} (Gene)", "DNTTIP2" ], [ "DNTTIP2", "{u} (Gene) is downregulated by {v} (Compound)", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Scopolamine" ], [ "Scopolamine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glycopyrronium" ], [ "Glycopyrronium", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hyoscyamine" ], [ "Hyoscyamine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenelzine" ] ], [ [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyclizine" ], [ "Cyclizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenelzine" ] ] ]
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Phenelzine (Compound) Cyproheptadine (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Phenelzine (Compound) Cyproheptadine (Compound) upregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Phenelzine (Compound) Cyproheptadine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Phenelzine (Compound) Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a minor interaction that can limit clinical effects when taken with Phenelzine Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Phenelzine Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a minor interaction that can limit clinical effects when taken with Phenelzine Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
DB01115
DB11978
336
124
[ "DDInter1291", "DDInter822" ]
Nifedipine
Glasdegib
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Moderate
1
[ [ [ 336, 24, 124 ] ], [ [ 336, 23, 1135 ], [ 1135, 23, 124 ] ], [ [ 336, 23, 466 ], [ 466, 62, 124 ] ], [ [ 336, 63, 475 ], [ 475, 24, 124 ] ], [ [ 336, 24, 98 ], [ 98, 24, 124 ] ], [ [ 336, 24, 159 ], [ 159, 63, 124 ] ], [ [ 336, 23, 578 ], [ 578, 24, 124 ] ], [ [ 336, 40, 376 ], [ 376, 24, 124 ] ], [ [ 336, 63, 702 ], [ 702, 25, 124 ] ], [ [ 336, 24, 982 ], [ 982, 64, 124 ] ] ]
[ [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ], [ "Somatrem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} (Compound) resembles {v} (Compound)", "Amlodipine" ], [ "Amlodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may lead to a major life threatening interaction when taken with {v}", "Glasdegib" ] ], [ [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Glasdegib" ] ] ]
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Nifedipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Glasdegib
DB00454
DB00757
1,349
1,166
[ "DDInter1150", "DDInter581" ]
Meperidine
Dolasetron
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Major
2
[ [ [ 1349, 25, 1166 ] ], [ [ 1349, 63, 19 ], [ 19, 40, 1166 ] ], [ [ 1349, 24, 85 ], [ 85, 1, 1166 ] ], [ [ 1349, 6, 12523 ], [ 12523, 45, 1166 ] ], [ [ 1349, 21, 28827 ], [ 28827, 60, 1166 ] ], [ [ 1349, 24, 752 ], [ 752, 23, 1166 ] ], [ [ 1349, 24, 214 ], [ 214, 63, 1166 ] ], [ [ 1349, 64, 475 ], [ 475, 24, 1166 ] ], [ [ 1349, 24, 401 ], [ 401, 64, 1166 ] ], [ [ 1349, 25, 222 ], [ 222, 64, 1166 ] ] ]
[ [ [ "Meperidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolasetron" ] ], [ [ "Meperidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hyoscyamine" ], [ "Hyoscyamine", "{u} (Compound) resembles {v} (Compound)", "Dolasetron" ] ], [ [ "Meperidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atropine" ], [ "Atropine", "{u} (Compound) resembles {v} (Compound)", "Dolasetron" ] ], [ [ "Meperidine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Dolasetron" ] ], [ [ "Meperidine", "{u} (Compound) causes {v} (Side Effect)", "Orthostatic hypotension" ], [ "Orthostatic hypotension", "{u} (Side Effect) is caused by {v} (Compound)", "Dolasetron" ] ], [ [ "Meperidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dolasetron" ] ], [ [ "Meperidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dolasetron" ] ], [ [ "Meperidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dolasetron" ] ], [ [ "Meperidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolasetron" ] ], [ [ "Meperidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolasetron" ] ] ]
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound) Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound) Meperidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dolasetron (Compound) Meperidine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Dolasetron (Compound) Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolasetron Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Dolasetron Meperidine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dolasetron
DB00104
DB13074
966
877
[ "DDInter1323", "DDInter1110" ]
Octreotide
Macimorelin
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Moderate
1
[ [ [ 966, 24, 877 ] ], [ [ 966, 63, 176 ], [ 176, 24, 877 ] ], [ [ 966, 24, 1296 ], [ 1296, 24, 877 ] ], [ [ 966, 25, 179 ], [ 179, 24, 877 ] ], [ [ 966, 24, 1375 ], [ 1375, 25, 877 ] ], [ [ 966, 40, 1154 ], [ 1154, 25, 877 ] ], [ [ 966, 63, 176 ], [ 176, 24, 1247 ], [ 1247, 23, 877 ] ], [ [ 966, 24, 1296 ], [ 1296, 63, 1247 ], [ 1247, 23, 877 ] ], [ [ 966, 25, 179 ], [ 179, 63, 1320 ], [ 1320, 24, 877 ] ], [ [ 966, 25, 1101 ], [ 1101, 24, 1320 ], [ 1320, 24, 877 ] ] ]
[ [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ], [ "Telotristat ethyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lefamulin" ], [ "Lefamulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} (Compound) resembles {v} (Compound)", "Pasireotide" ], [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ], [ "Telotristat ethyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Octreotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ] ]
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Octreotide may lead to a major life threatening interaction when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Macimorelin Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may lead to a major life threatening interaction when taken with Macimorelin Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin Octreotide may lead to a major life threatening interaction when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
DB00072
DB08880
550
1,510
[ "DDInter1846", "DDInter1771" ]
Trastuzumab
Teriflunomide
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI (
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Major
2
[ [ [ 550, 25, 1510 ] ], [ [ 550, 24, 221 ], [ 221, 63, 1510 ] ], [ [ 550, 24, 1136 ], [ 1136, 24, 1510 ] ], [ [ 550, 24, 713 ], [ 713, 64, 1510 ] ], [ [ 550, 25, 1066 ], [ 1066, 25, 1510 ] ], [ [ 550, 24, 973 ], [ 973, 25, 1510 ] ], [ [ 550, 63, 1184 ], [ 1184, 25, 1510 ] ], [ [ 550, 64, 1057 ], [ 1057, 25, 1510 ] ], [ [ 550, 25, 375 ], [ 375, 64, 1510 ] ], [ [ 550, 24, 221 ], [ 221, 63, 36 ], [ 36, 25, 1510 ] ] ]
[ [ [ "Trastuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Poliovirus type 1 antigen (formaldehyde inactivated)" ], [ "Poliovirus type 1 antigen (formaldehyde inactivated)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Denosumab" ], [ "Denosumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ], [ "Dimethyl fumarate", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ], [ "Paclitaxel", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ], [ [ "Trastuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Poliovirus type 1 antigen (formaldehyde inactivated)" ], [ "Poliovirus type 1 antigen (formaldehyde inactivated)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eribulin" ], [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ] ] ]
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Teriflunomide Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
DB00350
DB00418
1,214
536
[ "DDInter1226", "DDInter1650" ]
Minoxidil
Secobarbital
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.
Moderate
1
[ [ [ 1214, 24, 536 ] ], [ [ 1214, 24, 697 ], [ 697, 1, 536 ] ], [ [ 1214, 24, 593 ], [ 593, 63, 536 ] ], [ [ 1214, 24, 999 ], [ 999, 24, 536 ] ], [ [ 1214, 63, 1648 ], [ 1648, 24, 536 ] ], [ [ 1214, 63, 475 ], [ 475, 25, 536 ] ], [ [ 1214, 24, 697 ], [ 697, 40, 773 ], [ 773, 1, 536 ] ], [ [ 1214, 24, 593 ], [ 593, 63, 1023 ], [ 1023, 1, 536 ] ], [ [ 1214, 63, 1648 ], [ 1648, 24, 1023 ], [ 1023, 1, 536 ] ], [ [ 1214, 5, 11590 ], [ 11590, 49, 274 ], [ 274, 63, 536 ] ] ]
[ [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenobarbital" ], [ "Phenobarbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenobarbital" ], [ "Phenobarbital", "{u} (Compound) resembles {v} (Compound)", "Amobarbital" ], [ "Amobarbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentobarbital" ], [ "Pentobarbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ] ], [ [ "Minoxidil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentobarbital" ], [ "Pentobarbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ] ], [ [ "Minoxidil", "{u} (Compound) treats {v} (Disease)", "hypertension" ], [ "hypertension", "{u} (Disease) is palliated by {v} (Compound)", "Phentolamine" ], [ "Phentolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secobarbital" ] ] ]
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Secobarbital (Compound) Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Secobarbital Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound) Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound) Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound) Minoxidil (Compound) treats hypertension (Disease) and hypertension (Disease) is palliated by Phentolamine (Compound) and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
DB00994
DB01276
361
123
[ "DDInter1277", "DDInter706" ]
Neomycin
Exenatide
Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.[A175042,A191529] Neomycin A, or [neamine], is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Moderate
1
[ [ [ 361, 24, 123 ] ], [ [ 361, 62, 1252 ], [ 1252, 23, 123 ] ], [ [ 361, 24, 1332 ], [ 1332, 24, 123 ] ], [ [ 361, 24, 445 ], [ 445, 63, 123 ] ], [ [ 361, 25, 1329 ], [ 1329, 63, 123 ] ], [ [ 361, 63, 126 ], [ 126, 24, 123 ] ], [ [ 361, 64, 1028 ], [ 1028, 24, 123 ] ], [ [ 361, 35, 416 ], [ 416, 24, 123 ] ], [ [ 361, 62, 1252 ], [ 1252, 63, 1636 ], [ 1636, 24, 123 ] ], [ [ 361, 24, 1332 ], [ 1332, 24, 848 ], [ 848, 24, 123 ] ] ]
[ [ [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxyflurane" ], [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Givosiran" ], [ "Givosiran", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Gallium nitrate" ], [ "Gallium nitrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Torasemide" ], [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ], [ "Kanamycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylephrine" ], [ "Phenylephrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxyflurane" ], [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ], [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ] ]
Neomycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane and Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may lead to a major life threatening interaction when taken with Gallium nitrate and Gallium nitrate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin (Compound) resembles Kanamycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane and Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
DB09122
DB09570
1,613
1,480
[ "DDInter1409", "DDInter1002" ]
Peginterferon beta-1a
Ixazomib
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Moderate
1
[ [ [ 1613, 24, 1480 ] ], [ [ 1613, 63, 268 ], [ 268, 24, 1480 ] ], [ [ 1613, 64, 139 ], [ 139, 24, 1480 ] ], [ [ 1613, 24, 110 ], [ 110, 63, 1480 ] ], [ [ 1613, 63, 1236 ], [ 1236, 25, 1480 ] ], [ [ 1613, 64, 1377 ], [ 1377, 25, 1480 ] ], [ [ 1613, 63, 268 ], [ 268, 24, 440 ], [ 440, 24, 1480 ] ], [ [ 1613, 64, 139 ], [ 139, 64, 268 ], [ 268, 24, 1480 ] ], [ [ 1613, 24, 110 ], [ 110, 63, 440 ], [ 440, 24, 1480 ] ], [ [ 1613, 63, 482 ], [ 482, 24, 987 ], [ 987, 63, 1480 ] ] ]
[ [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2b" ], [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may lead to a major life threatening interaction when taken with {v}", "Zidovudine" ], [ "Zidovudine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ], [ "Polatuzumab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbamazepine" ], [ "Carbamazepine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2b" ], [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Filgrastim" ], [ "Filgrastim", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may lead to a major life threatening interaction when taken with {v}", "Zidovudine" ], [ "Zidovudine", "{u} may lead to a major life threatening interaction when taken with {v}", "Peginterferon alfa-2b" ], [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ], [ "Polatuzumab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Filgrastim" ], [ "Filgrastim", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tioguanine" ], [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ], [ "Vibrio cholerae CVD 103-HgR strain live antigen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ] ] ]
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Ixazomib Peginterferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ixazomib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
DB00656
DB14568
827
982
[ "DDInter1851", "DDInter1000" ]
Trazodone
Ivosidenib
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Major
2
[ [ [ 827, 25, 982 ] ], [ [ 827, 23, 112 ], [ 112, 23, 982 ] ], [ [ 827, 63, 1101 ], [ 1101, 23, 982 ] ], [ [ 827, 24, 543 ], [ 543, 24, 982 ] ], [ [ 827, 24, 159 ], [ 159, 63, 982 ] ], [ [ 827, 63, 355 ], [ 355, 24, 982 ] ], [ [ 827, 40, 673 ], [ 673, 24, 982 ] ], [ [ 827, 64, 11 ], [ 11, 25, 982 ] ], [ [ 827, 25, 1493 ], [ 1493, 25, 982 ] ], [ [ 827, 24, 124 ], [ 124, 25, 982 ] ] ]
[ [ [ "Trazodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lactulose" ], [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Aripiprazole" ], [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Halofantrine" ], [ "Halofantrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ], [ "Glasdegib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ] ]
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Trazodone (Compound) resembles Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Trazodone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib Trazodone may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Ivosidenib Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib
DB01028
DB09156
1,332
777
[ "DDInter1179", "DDInter964" ]
Methoxyflurane
Iopromide
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.
Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can cause several serious adverse effects, including cardiac events, thromboembolism, hypersensitivity reaction, and even death if administered intrathecally inadvertently, it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events. Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and orthography.[L46906,L46911]
Major
2
[ [ [ 1332, 25, 777 ] ], [ [ 1332, 63, 372 ], [ 372, 25, 777 ] ], [ [ 1332, 24, 712 ], [ 712, 25, 777 ] ], [ [ 1332, 64, 629 ], [ 629, 25, 777 ] ], [ [ 1332, 63, 372 ], [ 372, 63, 1648 ], [ 1648, 24, 777 ] ], [ [ 1332, 63, 1512 ], [ 1512, 24, 772 ], [ 772, 24, 777 ] ], [ [ 1332, 24, 712 ], [ 712, 24, 242 ], [ 242, 63, 777 ] ], [ [ 1332, 63, 50 ], [ 50, 24, 1074 ], [ 1074, 63, 777 ] ], [ [ 1332, 63, 1132 ], [ 1132, 64, 1028 ], [ 1028, 24, 777 ] ], [ [ 1332, 24, 848 ], [ 848, 24, 772 ], [ 772, 24, 777 ] ] ]
[ [ [ "Methoxyflurane", "{u} may lead to a major life threatening interaction when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olsalazine" ], [ "Olsalazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may lead to a major life threatening interaction when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ], [ "Carvedilol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olsalazine" ], [ "Olsalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remdesivir" ], [ "Remdesivir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfasalazine" ], [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ], [ "Iodide I-123", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gentamicin" ], [ "Gentamicin", "{u} may lead to a major life threatening interaction when taken with {v}", "Torasemide" ], [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ], [ [ "Methoxyflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ], [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ], [ "Carvedilol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iopromide" ] ] ]
Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Iopromide Methoxyflurane may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
DB00924
DB09076
1,405
1,116
[ "DDInter454", "DDInter1899" ]
Cyclobenzaprine
Umeclidinium
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. Parasympathetic ganglia are associated with the larger airways while postganglionic fibers innervate the smaller diameter bronchioles contributing to airway resistance. By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommended the use of two long-acting bronchodilators with differing mechanisms of action to maximize efficacy and minimize adverse effects.[A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. Later, it was further approved as a combination product with [vilanterol] and [vilanterol]/[fluticasone furoate] under the brand name ANORO ELLIPTA and TRELEGY ELLIPTA respectively.[L44461,L44456]. ANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886]
Moderate
1
[ [ [ 1405, 24, 1116 ] ], [ [ 1405, 24, 849 ], [ 849, 24, 1116 ] ], [ [ 1405, 40, 358 ], [ 358, 24, 1116 ] ], [ [ 1405, 63, 1442 ], [ 1442, 24, 1116 ] ], [ [ 1405, 25, 1264 ], [ 1264, 24, 1116 ] ], [ [ 1405, 24, 103 ], [ 103, 63, 1116 ] ], [ [ 1405, 74, 1594 ], [ 1594, 24, 1116 ] ], [ [ 1405, 24, 849 ], [ 849, 63, 1300 ], [ 1300, 24, 1116 ] ], [ [ 1405, 40, 358 ], [ 358, 24, 849 ], [ 849, 24, 1116 ] ], [ [ 1405, 24, 1511 ], [ 1511, 24, 849 ], [ 849, 24, 1116 ] ] ]
[ [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} (Compound) resembles {v} (Compound)", "Orphenadrine" ], [ "Orphenadrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Scopolamine" ], [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acrivastine" ], [ "Acrivastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Haloperidol" ], [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} (Compound) resembles {v} (Compound)", "Orphenadrine" ], [ "Orphenadrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ], [ [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ] ] ]
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine and Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine (Compound) resembles Doxylamine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
DB00501
DB11757
752
960
[ "DDInter380", "DDInter994" ]
Cimetidine
Istradefylline
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019.
Moderate
1
[ [ [ 752, 24, 960 ] ], [ [ 752, 23, 1135 ], [ 1135, 23, 960 ] ], [ [ 752, 24, 1419 ], [ 1419, 24, 960 ] ], [ [ 752, 24, 971 ], [ 971, 63, 960 ] ], [ [ 752, 25, 543 ], [ 543, 24, 960 ] ], [ [ 752, 64, 322 ], [ 322, 24, 960 ] ], [ [ 752, 24, 1456 ], [ 1456, 25, 960 ] ], [ [ 752, 23, 609 ], [ 609, 25, 960 ] ], [ [ 752, 23, 1135 ], [ 1135, 24, 1499 ], [ 1499, 24, 960 ] ], [ [ 752, 24, 1419 ], [ 1419, 25, 1135 ], [ 1135, 23, 960 ] ] ]
[ [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Venetoclax" ], [ "Venetoclax", "{u} may lead to a major life threatening interaction when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naldemedine" ], [ "Naldemedine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Istradefylline" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Istradefylline" ] ] ]
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline Cimetidine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Istradefylline Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Istradefylline Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
DB00722
DB06203
743
1,002
[ "DDInter1079", "DDInter51" ]
Lisinopril
Alogliptin
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Moderate
1
[ [ [ 743, 24, 1002 ] ], [ [ 743, 24, 1281 ], [ 1281, 40, 1002 ] ], [ [ 743, 21, 28873 ], [ 28873, 60, 1002 ] ], [ [ 743, 24, 401 ], [ 401, 24, 1002 ] ], [ [ 743, 63, 176 ], [ 176, 24, 1002 ] ], [ [ 743, 35, 1144 ], [ 1144, 24, 1002 ] ], [ [ 743, 24, 1019 ], [ 1019, 63, 1002 ] ], [ [ 743, 1, 1058 ], [ 1058, 24, 1002 ] ], [ [ 743, 40, 1638 ], [ 1638, 24, 1002 ] ], [ [ 743, 24, 1281 ], [ 1281, 6, 4405 ], [ 4405, 45, 1002 ] ] ]
[ [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Linagliptin" ], [ "Linagliptin", "{u} (Compound) resembles {v} (Compound)", "Alogliptin" ] ], [ [ "Lisinopril", "{u} (Compound) causes {v} (Side Effect)", "Pancreatitis" ], [ "Pancreatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Alogliptin" ] ], [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ], [ "Deflazacort", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Moexipril" ], [ "Moexipril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Trandolapril" ], [ "Trandolapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ] ], [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Linagliptin" ], [ "Linagliptin", "{u} (Compound) binds {v} (Gene)", "DPP4" ], [ "DPP4", "{u} (Gene) is bound by {v} (Compound)", "Alogliptin" ] ] ]
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound) Lisinopril (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound) Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril (Compound) resembles Nateglinide (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) binds DPP4 (Gene) and DPP4 (Gene) is bound by Alogliptin (Compound)
DB00486
DB00692
1,614
274
[ "DDInter1253", "DDInter1448" ]
Nabilone
Phentolamine
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
Moderate
1
[ [ [ 1614, 24, 274 ] ], [ [ 1614, 21, 29118 ], [ 29118, 60, 274 ] ], [ [ 1614, 63, 695 ], [ 695, 24, 274 ] ], [ [ 1614, 40, 530 ], [ 530, 24, 274 ] ], [ [ 1614, 24, 572 ], [ 572, 63, 274 ] ], [ [ 1614, 24, 87 ], [ 87, 24, 274 ] ], [ [ 1614, 25, 675 ], [ 675, 24, 274 ] ], [ [ 1614, 24, 876 ], [ 876, 64, 274 ] ], [ [ 1614, 21, 29118 ], [ 29118, 60, 530 ], [ 530, 24, 274 ] ], [ [ 1614, 21, 28658 ], [ 28658, 60, 572 ], [ 572, 63, 274 ] ] ]
[ [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} (Compound) causes {v} (Side Effect)", "Tachycardia" ], [ "Tachycardia", "{u} (Side Effect) is caused by {v} (Compound)", "Phentolamine" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} (Compound) resembles {v} (Compound)", "Dronabinol" ], [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenoldopam" ], [ "Fenoldopam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amoxapine" ], [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} may lead to a major life threatening interaction when taken with {v}", "Dextropropoxyphene" ], [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tizanidine" ], [ "Tizanidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} (Compound) causes {v} (Side Effect)", "Tachycardia" ], [ "Tachycardia", "{u} (Side Effect) is caused by {v} (Compound)", "Dronabinol" ], [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Nabilone", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Fenoldopam" ], [ "Fenoldopam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ] ]
Nabilone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam and Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Phentolamine Nabilone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Nabilone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Fenoldopam (Compound) and Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
DB00860
DB09048
891
555
[ "DDInter1513", "DDInter1284" ]
Prednisolone
Netupitant
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Moderate
1
[ [ [ 891, 24, 555 ] ], [ [ 891, 63, 1101 ], [ 1101, 23, 555 ] ], [ [ 891, 24, 283 ], [ 283, 62, 555 ] ], [ [ 891, 24, 473 ], [ 473, 24, 555 ] ], [ [ 891, 40, 1573 ], [ 1573, 24, 555 ] ], [ [ 891, 63, 1324 ], [ 1324, 24, 555 ] ], [ [ 891, 1, 175 ], [ 175, 24, 555 ] ], [ [ 891, 25, 676 ], [ 676, 63, 555 ] ], [ [ 891, 24, 159 ], [ 159, 63, 555 ] ], [ [ 891, 25, 976 ], [ 976, 24, 555 ] ] ]
[ [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ], [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ], [ [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Netupitant" ] ] ]
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Netupitant Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant Prednisolone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
DB01069
DB08897
401
1,429
[ "DDInter1533", "DDInter22" ]
Promethazine
Aclidinium
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Moderate
1
[ [ [ 401, 24, 1429 ] ], [ [ 401, 63, 352 ], [ 352, 24, 1429 ] ], [ [ 401, 24, 1511 ], [ 1511, 24, 1429 ] ], [ [ 401, 6, 4304 ], [ 4304, 45, 1429 ] ], [ [ 401, 21, 28817 ], [ 28817, 60, 1429 ] ], [ [ 401, 64, 1300 ], [ 1300, 24, 1429 ] ], [ [ 401, 35, 358 ], [ 358, 24, 1429 ] ], [ [ 401, 24, 1116 ], [ 1116, 63, 1429 ] ], [ [ 401, 74, 1630 ], [ 1630, 24, 1429 ] ], [ [ 401, 75, 684 ], [ 684, 24, 1429 ] ] ]
[ [ [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} (Compound) binds {v} (Gene)", "CHRM2" ], [ "CHRM2", "{u} (Gene) is bound by {v} (Compound)", "Aclidinium" ] ], [ [ "Promethazine", "{u} (Compound) causes {v} (Side Effect)", "Vision blurred" ], [ "Vision blurred", "{u} (Side Effect) is caused by {v} (Compound)", "Aclidinium" ] ], [ [ "Promethazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Haloperidol" ], [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orphenadrine" ], [ "Orphenadrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ], [ "Umeclidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perphenazine" ], [ "Perphenazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ], [ [ "Promethazine", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Thioridazine" ], [ "Thioridazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ] ] ]
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Aclidinium (Compound) Promethazine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Aclidinium (Compound) Promethazine may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine (Compound) resembles Perphenazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium Promethazine (Compound) resembles Thioridazine (Compound) and Promethazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
DB00227
DB00704
1,463
267
[ "DDInter1098", "DDInter1263" ]
Lovastatin
Naltrexone
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Moderate
1
[ [ [ 1463, 24, 267 ] ], [ [ 1463, 6, 4973 ], [ 4973, 45, 267 ] ], [ [ 1463, 7, 3163 ], [ 3163, 46, 267 ] ], [ [ 1463, 18, 2900 ], [ 2900, 46, 267 ] ], [ [ 1463, 18, 6168 ], [ 6168, 57, 267 ] ], [ [ 1463, 21, 28695 ], [ 28695, 60, 267 ] ], [ [ 1463, 24, 1583 ], [ 1583, 63, 267 ] ], [ [ 1463, 24, 522 ], [ 522, 24, 267 ] ], [ [ 1463, 40, 681 ], [ 681, 24, 267 ] ], [ [ 1463, 63, 912 ], [ 912, 24, 267 ] ] ]
[ [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) upregulates {v} (Gene)", "TSC22D3" ], [ "TSC22D3", "{u} (Gene) is upregulated by {v} (Compound)", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) downregulates {v} (Gene)", "NFKBIA" ], [ "NFKBIA", "{u} (Gene) is upregulated by {v} (Compound)", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) downregulates {v} (Gene)", "IGFBP3" ], [ "IGFBP3", "{u} (Gene) is downregulated by {v} (Compound)", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) causes {v} (Side Effect)", "Dyspnoea" ], [ "Dyspnoea", "{u} (Side Effect) is caused by {v} (Compound)", "Naltrexone" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarilumab" ], [ "Sarilumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Zafirlukast" ], [ "Zafirlukast", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ] ], [ [ "Lovastatin", "{u} (Compound) resembles {v} (Compound)", "Pravastatin" ], [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ] ] ]
Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound) Lovastatin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Naltrexone (Compound) Lovastatin (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Naltrexone (Compound) Lovastatin (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Naltrexone (Compound) Lovastatin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound) Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone Lovastatin (Compound) resembles Pravastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
DB00009
DB00500
1,271
24
[ "DDInter56", "DDInter1831" ]
Alteplase
Tolmetin
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem
A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Moderate
1
[ [ [ 1271, 24, 24 ] ], [ [ 1271, 24, 886 ], [ 886, 1, 24 ] ], [ [ 1271, 24, 831 ], [ 831, 40, 24 ] ], [ [ 1271, 25, 1432 ], [ 1432, 24, 24 ] ], [ [ 1271, 24, 121 ], [ 121, 63, 24 ] ], [ [ 1271, 25, 936 ], [ 936, 63, 24 ] ], [ [ 1271, 24, 1061 ], [ 1061, 24, 24 ] ], [ [ 1271, 64, 942 ], [ 942, 24, 24 ] ], [ [ 1271, 25, 1409 ], [ 1409, 64, 24 ] ], [ [ 1271, 25, 834 ], [ 834, 25, 24 ] ] ]
[ [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ketorolac" ], [ "Ketorolac", "{u} (Compound) resembles {v} (Compound)", "Tolmetin" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Indomethacin" ], [ "Indomethacin", "{u} (Compound) resembles {v} (Compound)", "Tolmetin" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Abciximab" ], [ "Abciximab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenfluramine" ], [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Cangrelor" ], [ "Cangrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Treprostinil" ], [ "Treprostinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Apixaban" ], [ "Apixaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Tolmetin" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Drotrecogin alfa" ], [ "Drotrecogin alfa", "{u} may lead to a major life threatening interaction when taken with {v}", "Tolmetin" ] ] ]
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound) Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compound) Alteplase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin Alteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin Alteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin Alteplase may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Tolmetin Alteplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Tolmetin
DB00501
DB08932
752
1,398
[ "DDInter380", "DDInter1111" ]
Cimetidine
Macitentan
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity.
Moderate
1
[ [ [ 752, 24, 1398 ] ], [ [ 752, 6, 8374 ], [ 8374, 45, 1398 ] ], [ [ 752, 21, 28762 ], [ 28762, 60, 1398 ] ], [ [ 752, 24, 283 ], [ 283, 63, 1398 ] ], [ [ 752, 24, 1478 ], [ 1478, 24, 1398 ] ], [ [ 752, 25, 1250 ], [ 1250, 24, 1398 ] ], [ [ 752, 23, 609 ], [ 609, 25, 1398 ] ], [ [ 752, 24, 1510 ], [ 1510, 25, 1398 ] ], [ [ 752, 6, 8374 ], [ 8374, 45, 1478 ], [ 1478, 24, 1398 ] ], [ [ 752, 21, 28762 ], [ 28762, 60, 1478 ], [ 1478, 24, 1398 ] ] ]
[ [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Macitentan" ] ], [ [ "Cimetidine", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Macitentan" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ], [ [ "Cimetidine", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macitentan" ] ] ]
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound) Cimetidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Macitentan (Compound) Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Macitentan Cimetidine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Macitentan Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Macitentan Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Macitentan Cimetidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
DB00978
DB13928
739
1,385
[ "DDInter1084", "DDInter1660" ]
Lomefloxacin
Semaglutide
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Moderate
1
[ [ [ 739, 24, 1385 ] ], [ [ 739, 25, 1154 ], [ 1154, 24, 1385 ] ], [ [ 739, 64, 891 ], [ 891, 24, 1385 ] ], [ [ 739, 1, 872 ], [ 872, 24, 1385 ] ], [ [ 739, 24, 1148 ], [ 1148, 24, 1385 ] ], [ [ 739, 63, 485 ], [ 485, 24, 1385 ] ], [ [ 739, 40, 1299 ], [ 1299, 24, 1385 ] ], [ [ 739, 1, 246 ], [ 246, 25, 1385 ] ], [ [ 739, 25, 1154 ], [ 1154, 25, 1399 ], [ 1399, 63, 1385 ] ], [ [ 739, 64, 891 ], [ 891, 40, 1103 ], [ 1103, 23, 1385 ] ] ]
[ [ [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ], [ "Gemifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Trovafloxacin" ], [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lithium carbonate" ], [ "Lithium carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ] ], [ [ "Lomefloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Semaglutide" ] ] ]
Lomefloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Semaglutide Lomefloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide Lomefloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
DB00322
DB01030
141
869
[ "DDInter742", "DDInter1835" ]
Floxuridine
Topotecan
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Moderate
1
[ [ [ 141, 24, 869 ] ], [ [ 141, 7, 6628 ], [ 6628, 46, 869 ] ], [ [ 141, 18, 3848 ], [ 3848, 57, 869 ] ], [ [ 141, 7, 2942 ], [ 2942, 57, 869 ] ], [ [ 141, 21, 29276 ], [ 29276, 60, 869 ] ], [ [ 141, 23, 872 ], [ 872, 62, 869 ] ], [ [ 141, 23, 1467 ], [ 1467, 23, 869 ] ], [ [ 141, 62, 1176 ], [ 1176, 23, 869 ] ], [ [ 141, 24, 995 ], [ 995, 24, 869 ] ], [ [ 141, 24, 1270 ], [ 1270, 63, 869 ] ] ]
[ [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ] ], [ [ "Floxuridine", "{u} (Compound) upregulates {v} (Gene)", "PMAIP1" ], [ "PMAIP1", "{u} (Gene) is upregulated by {v} (Compound)", "Topotecan" ] ], [ [ "Floxuridine", "{u} (Compound) downregulates {v} (Gene)", "CDKN3" ], [ "CDKN3", "{u} (Gene) is downregulated by {v} (Compound)", "Topotecan" ] ], [ [ "Floxuridine", "{u} (Compound) upregulates {v} (Gene)", "KEAP1" ], [ "KEAP1", "{u} (Gene) is downregulated by {v} (Compound)", "Topotecan" ] ], [ [ "Floxuridine", "{u} (Compound) causes {v} (Side Effect)", "Haemoglobin" ], [ "Haemoglobin", "{u} (Side Effect) is caused by {v} (Compound)", "Topotecan" ] ], [ [ "Floxuridine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gemifloxacin" ], [ "Gemifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Topotecan" ] ], [ [ "Floxuridine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Enoxacin" ], [ "Enoxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Topotecan" ] ], [ [ "Floxuridine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Moxifloxacin" ], [ "Moxifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Topotecan" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyurea" ], [ "Hydroxyurea", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ], [ "Tuberculin purified protein derivative", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ] ] ]
Floxuridine (Compound) upregulates PMAIP1 (Gene) and PMAIP1 (Gene) is upregulated by Topotecan (Compound) Floxuridine (Compound) downregulates CDKN3 (Gene) and CDKN3 (Gene) is downregulated by Topotecan (Compound) Floxuridine (Compound) upregulates KEAP1 (Gene) and KEAP1 (Gene) is downregulated by Topotecan (Compound) Floxuridine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound) Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan Floxuridine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan Floxuridine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
DB00115
DB00863
227
1,194
[ "DDInter451", "DDInter1568" ]
Cyanocobalamin
Ranitidine
Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria, and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. The _cyano_ form, is the most widely used form in supplements and prescription drugs, [FDA label]. Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms [FDA label],,. This drug was initially approved by the FDA in 1942 [FDA label].
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Minor
0
[ [ [ 227, 23, 1194 ] ], [ [ 227, 23, 1127 ], [ 1127, 1, 1194 ] ], [ [ 227, 1, 204 ], [ 204, 21, 28741 ], [ 28741, 60, 1194 ] ], [ [ 227, 23, 1127 ], [ 1127, 6, 4973 ], [ 4973, 45, 1194 ] ], [ [ 227, 6, 4557 ], [ 4557, 17, 3385 ], [ 3385, 57, 1194 ] ], [ [ 227, 6, 4182 ], [ 4182, 0, 6797 ], [ 6797, 57, 1194 ] ], [ [ 227, 23, 1127 ], [ 1127, 54, 19263 ], [ 19263, 15, 1194 ] ], [ [ 227, 6, 4182 ], [ 4182, 46, 1213 ], [ 1213, 64, 1194 ] ], [ [ 227, 23, 1127 ], [ 1127, 18, 6718 ], [ 6718, 57, 1194 ] ], [ [ 227, 23, 1621 ], [ 1621, 21, 28809 ], [ 28809, 60, 1194 ] ] ]
[ [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nizatidine" ], [ "Nizatidine", "{u} (Compound) resembles {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} (Compound) resembles {v} (Compound)", "Hydroxocobalamin" ], [ "Hydroxocobalamin", "{u} (Compound) causes {v} (Side Effect)", "Agitation" ], [ "Agitation", "{u} (Side Effect) is caused by {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nizatidine" ], [ "Nizatidine", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} (Compound) binds {v} (Gene)", "MTR" ], [ "MTR", "{u} (Gene) regulates {v} (Gene)", "SDC1" ], [ "SDC1", "{u} (Gene) is downregulated by {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} (Compound) binds {v} (Gene)", "CASP9" ], [ "CASP9", "{u} (Gene) interacts with {v} (Gene)", "CYCS" ], [ "CYCS", "{u} (Gene) is downregulated by {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nizatidine" ], [ "Nizatidine", "{u} (Compound) is included by {v} (Pharmacologic Class)", "Histamine H2 Receptor Antagonists" ], [ "Histamine H2 Receptor Antagonists", "{u} (Pharmacologic Class) includes {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} (Compound) binds {v} (Gene)", "CASP9" ], [ "CASP9", "{u} (Gene) is upregulated by {v} (Compound)", "Dasatinib" ], [ "Dasatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nizatidine" ], [ "Nizatidine", "{u} (Compound) downregulates {v} (Gene)", "USP22" ], [ "USP22", "{u} (Gene) is downregulated by {v} (Compound)", "Ranitidine" ] ], [ [ "Cyanocobalamin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Potassium chloride" ], [ "Potassium chloride", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Ranitidine" ] ] ]
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound) Cyanocobalamin (Compound) resembles Hydroxocobalamin (Compound) and Hydroxocobalamin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Ranitidine (Compound) Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ranitidine (Compound) Cyanocobalamin (Compound) binds MTR (Gene) and MTR (Gene) regulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Ranitidine (Compound) Cyanocobalamin (Compound) binds CASP9 (Gene) and CASP9 (Gene) interacts with CYCS (Gene) and CYCS (Gene) is downregulated by Ranitidine (Compound) Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class) and Histamine H2 Receptor Antagonists (Pharmacologic Class) includes Ranitidine (Compound) Cyanocobalamin (Compound) binds CASP9 (Gene) and CASP9 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Ranitidine Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ranitidine (Compound) Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Ranitidine (Compound)
DB00175
DB01097
681
1,377
[ "DDInter1509", "DDInter1033" ]
Pravastatin
Leflunomide
Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Major
2
[ [ [ 681, 25, 1377 ] ], [ [ 681, 6, 6017 ], [ 6017, 45, 1377 ] ], [ [ 681, 21, 29405 ], [ 29405, 60, 1377 ] ], [ [ 681, 23, 126 ], [ 126, 24, 1377 ] ], [ [ 681, 24, 597 ], [ 597, 24, 1377 ] ], [ [ 681, 24, 1434 ], [ 1434, 63, 1377 ] ], [ [ 681, 24, 1491 ], [ 1491, 64, 1377 ] ], [ [ 681, 24, 629 ], [ 629, 25, 1377 ] ], [ [ 681, 63, 1057 ], [ 1057, 25, 1377 ] ], [ [ 681, 25, 1668 ], [ 1668, 25, 1377 ] ] ]
[ [ [ "Pravastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Leflunomide" ] ], [ [ "Pravastatin", "{u} (Compound) causes {v} (Side Effect)", "Raised liver function tests" ], [ "Raised liver function tests", "{u} (Side Effect) is caused by {v} (Compound)", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ], [ "Benznidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ] ], [ [ "Pravastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lenalidomide" ], [ "Lenalidomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ] ] ]
Pravastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound) Pravastatin (Compound) causes Raised liver function tests (Side Effect) and Raised liver function tests (Side Effect) is caused by Leflunomide (Compound) Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Leflunomide Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Leflunomide Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Leflunomide Pravastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may lead to a major life threatening interaction when taken with Leflunomide
DB00726
DB05381
1,164
172
[ "DDInter1876", "DDInter863" ]
Trimipramine
Histamine
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Moderate
1
[ [ [ 1164, 24, 172 ] ], [ [ 1164, 35, 1264 ], [ 1264, 24, 172 ] ], [ [ 1164, 1, 1237 ], [ 1237, 24, 172 ] ], [ [ 1164, 63, 1242 ], [ 1242, 24, 172 ] ], [ [ 1164, 24, 849 ], [ 849, 63, 172 ] ], [ [ 1164, 24, 830 ], [ 830, 24, 172 ] ], [ [ 1164, 35, 1264 ], [ 1264, 35, 1237 ], [ 1237, 24, 172 ] ], [ [ 1164, 1, 1237 ], [ 1237, 74, 1264 ], [ 1264, 24, 172 ] ], [ [ 1164, 63, 1242 ], [ 1242, 24, 1264 ], [ 1264, 24, 172 ] ], [ [ 1164, 24, 849 ], [ 849, 63, 1264 ], [ 1264, 24, 172 ] ] ]
[ [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} (Compound) resembles {v} (Compound)", "Clomipramine" ], [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenindamine" ], [ "Phenindamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clomipramine" ], [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} (Compound) resembles {v} (Compound)", "Clomipramine" ], [ "Clomipramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ], [ [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histamine" ] ] ]
Trimipramine (Compound) resembles Doxepin (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine (Compound) resembles Doxepin (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin (Compound) resembles Clomipramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine (Compound) resembles Clomipramine (Compound) and Clomipramine (Compound) resembles Doxepin (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
DB00295
DB09268
475
1,662
[ "DDInter1244", "DDInter1464" ]
Morphine
Picosulfuric acid
Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.
Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.
Moderate
1
[ [ [ 475, 24, 1662 ] ], [ [ 475, 24, 1164 ], [ 1164, 24, 1662 ] ], [ [ 475, 25, 776 ], [ 776, 24, 1662 ] ], [ [ 475, 24, 913 ], [ 913, 63, 1662 ] ], [ [ 475, 64, 534 ], [ 534, 24, 1662 ] ], [ [ 475, 25, 180 ], [ 180, 63, 1662 ] ], [ [ 475, 40, 1516 ], [ 1516, 24, 1662 ] ], [ [ 475, 36, 560 ], [ 560, 24, 1662 ] ], [ [ 475, 63, 1100 ], [ 1100, 24, 1662 ] ], [ [ 475, 23, 22 ], [ 22, 24, 1662 ] ] ]
[ [ [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Molindone" ], [ "Molindone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ], [ "Tramadol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Oliceridine" ], [ "Oliceridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} (Compound) resembles {v} (Compound)", "Galantamine" ], [ "Galantamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Oxymorphone" ], [ "Oxymorphone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Venlafaxine" ], [ "Venlafaxine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Morphine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ephedrine" ], [ "Ephedrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ] ]
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may lead to a major life threatening interaction when taken with Molindone and Molindone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine (Compound) resembles Oxymorphone (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxymorphone and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Morphine may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
DB00780
DB01041
551
770
[ "DDInter1440", "DDInter1789" ]
Phenelzine
Thalidomide
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Moderate
1
[ [ [ 551, 24, 770 ] ], [ [ 551, 6, 6365 ], [ 6365, 45, 770 ] ], [ [ 551, 21, 28714 ], [ 28714, 60, 770 ] ], [ [ 551, 24, 849 ], [ 849, 63, 770 ] ], [ [ 551, 1, 633 ], [ 633, 63, 770 ] ], [ [ 551, 63, 1614 ], [ 1614, 24, 770 ] ], [ [ 551, 25, 407 ], [ 407, 63, 770 ] ], [ [ 551, 64, 1494 ], [ 1494, 24, 770 ] ], [ [ 551, 24, 104 ], [ 104, 24, 770 ] ], [ [ 551, 25, 1133 ], [ 1133, 24, 770 ] ] ]
[ [ [ "Phenelzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} (Compound) binds {v} (Gene)", "CYP2E1" ], [ "CYP2E1", "{u} (Gene) is bound by {v} (Compound)", "Thalidomide" ] ], [ [ "Phenelzine", "{u} (Compound) causes {v} (Side Effect)", "Asthenia" ], [ "Asthenia", "{u} (Side Effect) is caused by {v} (Compound)", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} (Compound) resembles {v} (Compound)", "Lisdexamfetamine" ], [ "Lisdexamfetamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Palonosetron" ], [ "Palonosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ], [ [ "Phenelzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Granisetron" ], [ "Granisetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ] ] ]
Phenelzine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound) Phenelzine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Thalidomide (Compound) Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide Phenelzine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
DB00241
DB00279
288
1,152
[ "DDInter257", "DDInter1074" ]
Butalbital
Liothyronine
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.
Moderate
1
[ [ [ 288, 24, 1152 ] ], [ [ 288, 24, 542 ], [ 542, 40, 1152 ] ], [ [ 288, 24, 1031 ], [ 1031, 24, 1152 ] ], [ [ 288, 24, 761 ], [ 761, 63, 1152 ] ], [ [ 288, 1, 536 ], [ 536, 63, 1152 ] ], [ [ 288, 25, 126 ], [ 126, 63, 1152 ] ], [ [ 288, 40, 1023 ], [ 1023, 63, 1152 ] ], [ [ 288, 24, 542 ], [ 542, 40, 624 ], [ 624, 40, 1152 ] ], [ [ 288, 24, 1031 ], [ 1031, 24, 624 ], [ 624, 40, 1152 ] ], [ [ 288, 24, 761 ], [ 761, 63, 624 ], [ 624, 40, 1152 ] ] ]
[ [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levothyroxine" ], [ "Levothyroxine", "{u} (Compound) resembles {v} (Compound)", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ], [ "Secobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} (Compound) resembles {v} (Compound)", "Pentobarbital" ], [ "Pentobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levothyroxine" ], [ "Levothyroxine", "{u} (Compound) resembles {v} (Compound)", "Liotrix" ], [ "Liotrix", "{u} (Compound) resembles {v} (Compound)", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liotrix" ], [ "Liotrix", "{u} (Compound) resembles {v} (Compound)", "Liothyronine" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liotrix" ], [ "Liotrix", "{u} (Compound) resembles {v} (Compound)", "Liothyronine" ] ] ]
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liothyronine (Compound) Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound) and Liotrix (Compound) resembles Liothyronine (Compound) Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Liothyronine (Compound) Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Liothyronine (Compound)
DB00359
DB09293
161
116
[ "DDInter1721", "DDInter954" ]
Sulfadiazine
Iodide I-131
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function.
Moderate
1
[ [ [ 161, 24, 116 ] ], [ [ 161, 1, 1247 ], [ 1247, 24, 116 ] ], [ [ 161, 25, 126 ], [ 126, 24, 116 ] ], [ [ 161, 63, 929 ], [ 929, 24, 116 ] ], [ [ 161, 74, 10 ], [ 10, 24, 116 ] ], [ [ 161, 24, 1411 ], [ 1411, 24, 116 ] ], [ [ 161, 1, 1247 ], [ 1247, 23, 1487 ], [ 1487, 24, 116 ] ], [ [ 161, 25, 126 ], [ 126, 24, 1486 ], [ 1486, 24, 116 ] ], [ [ 161, 1, 698 ], [ 698, 1, 1247 ], [ 1247, 24, 116 ] ], [ [ 161, 63, 929 ], [ 929, 24, 1247 ], [ 1247, 24, 116 ] ] ]
[ [ [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} (Compound) resembles {v} (Compound)", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pyrimethamine" ], [ "Pyrimethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapsone" ], [ "Dapsone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} (Compound) resembles {v} (Compound)", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} (Compound) resembles {v} (Compound)", "Sulfadoxine" ], [ "Sulfadoxine", "{u} (Compound) resembles {v} (Compound)", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pyrimethamine" ], [ "Pyrimethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ] ]
Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimethamine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine (Compound) resembles Dapsone (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine (Compound) resembles Sulfadoxine (Compound) and Sulfadoxine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimethamine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
DB06777
DB08886
780
637
[ "DDInter348", "DDInter126" ]
Chenodeoxycholic acid
Asparaginase Erwinia chrysanthemi
Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.
Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase.
Moderate
1
[ [ [ 780, 24, 637 ] ], [ [ 780, 24, 850 ], [ 850, 24, 637 ] ], [ [ 780, 63, 267 ], [ 267, 24, 637 ] ], [ [ 780, 24, 1613 ], [ 1613, 63, 637 ] ], [ [ 780, 25, 1510 ], [ 1510, 25, 637 ] ], [ [ 780, 64, 1377 ], [ 1377, 25, 637 ] ], [ [ 780, 24, 850 ], [ 850, 63, 640 ], [ 640, 24, 637 ] ], [ [ 780, 63, 267 ], [ 267, 63, 640 ], [ 640, 24, 637 ] ], [ [ 780, 63, 663 ], [ 663, 64, 640 ], [ 640, 24, 637 ] ], [ [ 780, 63, 482 ], [ 482, 24, 640 ], [ 640, 24, 637 ] ] ]
[ [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ], [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acitretin" ], [ "Acitretin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acitretin" ], [ "Acitretin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may lead to a major life threatening interaction when taken with {v}", "Acitretin" ], [ "Acitretin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ], [ [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tioguanine" ], [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acitretin" ], [ "Acitretin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Erwinia chrysanthemi" ] ] ]
Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
DB00214
DB01050
1,028
848
[ "DDInter1836", "DDInter900" ]
Torasemide
Ibuprofen
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.
Moderate
1
[ [ [ 1028, 24, 848 ] ], [ [ 1028, 24, 1053 ], [ 1053, 1, 848 ] ], [ [ 1028, 6, 10522 ], [ 10522, 45, 848 ] ], [ [ 1028, 21, 28864 ], [ 28864, 60, 848 ] ], [ [ 1028, 24, 286 ], [ 286, 62, 848 ] ], [ [ 1028, 24, 590 ], [ 590, 24, 848 ] ], [ [ 1028, 24, 1619 ], [ 1619, 63, 848 ] ], [ [ 1028, 64, 1314 ], [ 1314, 24, 848 ] ], [ [ 1028, 25, 416 ], [ 416, 63, 848 ] ], [ [ 1028, 23, 1347 ], [ 1347, 24, 848 ] ] ]
[ [ [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} (Compound) resembles {v} (Compound)", "Ibuprofen" ] ], [ [ "Torasemide", "{u} (Compound) binds {v} (Gene)", "PTGS1" ], [ "PTGS1", "{u} (Gene) is bound by {v} (Compound)", "Ibuprofen" ] ], [ [ "Torasemide", "{u} (Compound) causes {v} (Side Effect)", "Erythema multiforme" ], [ "Erythema multiforme", "{u} (Side Effect) is caused by {v} (Compound)", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetohexamide" ], [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may lead to a major life threatening interaction when taken with {v}", "Desmopressin" ], [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may lead to a major life threatening interaction when taken with {v}", "Kanamycin" ], [ "Kanamycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ], [ [ "Torasemide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ] ] ]
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound) Torasemide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Ibuprofen (Compound) Torasemide (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Ibuprofen (Compound) Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Ibuprofen Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen Torasemide may lead to a major life threatening interaction when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen Torasemide may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen Torasemide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
DB00283
DB00486
701
1,614
[ "DDInter395", "DDInter1253" ]
Clemastine
Nabilone
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Nabilone or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function . In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.
Moderate
1
[ [ [ 701, 24, 1614 ] ], [ [ 701, 24, 530 ], [ 530, 1, 1614 ] ], [ [ 701, 21, 28769 ], [ 28769, 60, 1614 ] ], [ [ 701, 24, 999 ], [ 999, 24, 1614 ] ], [ [ 701, 24, 94 ], [ 94, 63, 1614 ] ], [ [ 701, 63, 1230 ], [ 1230, 24, 1614 ] ], [ [ 701, 35, 1242 ], [ 1242, 24, 1614 ] ], [ [ 701, 35, 252 ], [ 252, 63, 1614 ] ], [ [ 701, 25, 306 ], [ 306, 63, 1614 ] ], [ [ 701, 24, 1301 ], [ 1301, 64, 1614 ] ] ]
[ [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronabinol" ], [ "Dronabinol", "{u} (Compound) resembles {v} (Compound)", "Nabilone" ] ], [ [ "Clemastine", "{u} (Compound) causes {v} (Side Effect)", "Feeling abnormal" ], [ "Feeling abnormal", "{u} (Side Effect) is caused by {v} (Compound)", "Nabilone" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenacemide" ], [ "Phenacemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Citalopram" ], [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyzine" ], [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} may lead to a major life threatening interaction when taken with {v}", "Zonisamide" ], [ "Zonisamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levacetylmethadol" ], [ "Levacetylmethadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Nabilone" ] ] ]
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound) Clemastine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Nabilone (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine (Compound) resembles Hydroxyzine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol may lead to a major life threatening interaction when taken with Nabilone
DB00414
DB00736
590
660
[ "DDInter16", "DDInter676" ]
Acetohexamide
Esomeprazole
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including , , and , for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including , , , , and . Esomeprazole is the s-isomer of , which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as , without any significant differences between the two compounds _in vitro_. Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.[FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life. Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect.
Minor
0
[ [ [ 590, 23, 660 ] ], [ [ 590, 24, 972 ], [ 972, 62, 660 ] ], [ [ 590, 63, 168 ], [ 168, 23, 660 ] ], [ [ 590, 24, 1327 ], [ 1327, 63, 660 ] ], [ [ 590, 63, 529 ], [ 529, 24, 660 ] ], [ [ 590, 24, 811 ], [ 811, 24, 660 ] ], [ [ 590, 25, 1622 ], [ 1622, 24, 660 ] ], [ [ 590, 64, 600 ], [ 600, 24, 660 ] ], [ [ 590, 24, 915 ], [ 915, 64, 660 ] ], [ [ 590, 63, 798 ], [ 798, 25, 660 ] ] ]
[ [ [ "Acetohexamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Choline salicylate" ], [ "Choline salicylate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saquinavir" ], [ "Saquinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metolazone" ], [ "Metolazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Voriconazole" ], [ "Voriconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ], [ "Atazanavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Esomeprazole" ] ], [ [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nelfinavir" ], [ "Nelfinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Esomeprazole" ] ] ]
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a minor interaction that can limit clinical effects when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole Acetohexamide may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole Acetohexamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Esomeprazole Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may lead to a major life threatening interaction when taken with Esomeprazole
DB01242
DB09272
1,237
412
[ "DDInter410", "DDInter632" ]
Clomipramine
Eluxadoline
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale.
Moderate
1
[ [ [ 1237, 24, 412 ] ], [ [ 1237, 63, 1594 ], [ 1594, 24, 412 ] ], [ [ 1237, 24, 830 ], [ 830, 24, 412 ] ], [ [ 1237, 40, 21 ], [ 21, 24, 412 ] ], [ [ 1237, 24, 407 ], [ 407, 63, 412 ] ], [ [ 1237, 64, 593 ], [ 593, 24, 412 ] ], [ [ 1237, 1, 146 ], [ 146, 24, 412 ] ], [ [ 1237, 74, 662 ], [ 662, 24, 412 ] ], [ [ 1237, 24, 392 ], [ 392, 25, 412 ] ], [ [ 1237, 63, 1594 ], [ 1594, 24, 1105 ], [ 1105, 24, 412 ] ] ]
[ [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenindamine" ], [ "Phenindamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} (Compound) resembles {v} (Compound)", "Amitriptyline" ], [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} (Compound) resembles {v} (Compound)", "Propiomazine" ], [ "Propiomazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Eluxadoline" ] ], [ [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trihexyphenidyl" ], [ "Trihexyphenidyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eluxadoline" ] ] ]
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine (Compound) resembles Carbinoxamine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Eluxadoline Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
DB00705
DB08816
441
578
[ "DDInter496", "DDInter1802" ]
Delavirdine
Ticagrelor
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Major
2
[ [ [ 441, 25, 578 ] ], [ [ 441, 6, 8374 ], [ 8374, 45, 578 ] ], [ [ 441, 21, 28645 ], [ 28645, 60, 578 ] ], [ [ 441, 25, 1135 ], [ 1135, 62, 578 ] ], [ [ 441, 63, 723 ], [ 723, 24, 578 ] ], [ [ 441, 24, 868 ], [ 868, 63, 578 ] ], [ [ 441, 24, 1220 ], [ 1220, 24, 578 ] ], [ [ 441, 25, 1297 ], [ 1297, 63, 578 ] ], [ [ 441, 25, 617 ], [ 617, 24, 578 ] ], [ [ 441, 64, 1425 ], [ 1425, 24, 578 ] ] ]
[ [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} (Compound) causes {v} (Side Effect)", "Cough" ], [ "Cough", "{u} (Side Effect) is caused by {v} (Compound)", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Osilodrostat" ], [ "Osilodrostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ], [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Cisapride" ], [ "Cisapride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ] ] ]
Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound) Delavirdine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound) Delavirdine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor Delavirdine may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor Delavirdine may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor Delavirdine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
DB00673
DB01006
723
300
[ "DDInter112", "DDInter1040" ]
Aprepitant
Letrozole
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Moderate
1
[ [ [ 723, 24, 300 ] ], [ [ 723, 10, 11579 ], [ 11579, 44, 300 ] ], [ [ 723, 6, 8374 ], [ 8374, 45, 300 ] ], [ [ 723, 21, 28646 ], [ 28646, 60, 300 ] ], [ [ 723, 23, 307 ], [ 307, 23, 300 ] ], [ [ 723, 24, 697 ], [ 697, 62, 300 ] ], [ [ 723, 24, 441 ], [ 441, 23, 300 ] ], [ [ 723, 23, 1627 ], [ 1627, 62, 300 ] ], [ [ 723, 24, 1155 ], [ 1155, 63, 300 ] ], [ [ 723, 24, 1080 ], [ 1080, 24, 300 ] ] ]
[ [ [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} (Compound) palliates {v} (Disease)", "breast cancer" ], [ "breast cancer", "{u} (Disease) is treated by {v} (Compound)", "Letrozole" ] ], [ [ "Aprepitant", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Letrozole" ] ], [ [ "Aprepitant", "{u} (Compound) causes {v} (Side Effect)", "Unspecified disorder of skin and subcutaneous tissue" ], [ "Unspecified disorder of skin and subcutaneous tissue", "{u} (Side Effect) is caused by {v} (Compound)", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Modafinil" ], [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenobarbital" ], [ "Phenobarbital", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ], [ "Delavirdine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cannabidiol" ], [ "Cannabidiol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tucatinib" ], [ "Tucatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Letrozole" ] ], [ [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Conivaptan" ], [ "Conivaptan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Letrozole" ] ] ]
Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Letrozole (Compound) Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound) Aprepitant (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Letrozole (Compound) Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Letrozole Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Letrozole Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Letrozole Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Letrozole Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
DB00612
DB09481
1,121
460
[ "DDInter216", "DDInter1113" ]
Bisoprolol
Magnesium carbonate
Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.
Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].
Minor
0
[ [ [ 1121, 23, 460 ] ], [ [ 1121, 24, 401 ], [ 401, 23, 460 ] ], [ [ 1121, 63, 999 ], [ 999, 23, 460 ] ], [ [ 1121, 1, 887 ], [ 887, 23, 460 ] ], [ [ 1121, 63, 245 ], [ 245, 24, 460 ] ], [ [ 1121, 24, 959 ], [ 959, 24, 460 ] ], [ [ 1121, 23, 1479 ], [ 1479, 24, 460 ] ], [ [ 1121, 62, 542 ], [ 542, 24, 460 ] ], [ [ 1121, 24, 401 ], [ 401, 63, 664 ], [ 664, 23, 460 ] ], [ [ 1121, 63, 999 ], [ 999, 24, 664 ], [ 664, 23, 460 ] ] ]
[ [ [ "Bisoprolol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} (Compound) resembles {v} (Compound)", "Pindolol" ], [ "Pindolol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levothyroxine" ], [ "Levothyroxine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perindopril" ], [ "Perindopril", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Bisoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perindopril" ], [ "Perindopril", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ] ]
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Bisoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
DB06663
DB09073
1,154
951
[ "DDInter1398", "DDInter1379" ]
Pasireotide
Palbociclib
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Moderate
1
[ [ [ 1154, 24, 951 ] ], [ [ 1154, 23, 907 ], [ 907, 62, 951 ] ], [ [ 1154, 64, 318 ], [ 318, 23, 951 ] ], [ [ 1154, 63, 479 ], [ 479, 23, 951 ] ], [ [ 1154, 24, 159 ], [ 159, 63, 951 ] ], [ [ 1154, 25, 351 ], [ 351, 63, 951 ] ], [ [ 1154, 64, 1251 ], [ 1251, 24, 951 ] ], [ [ 1154, 63, 761 ], [ 761, 24, 951 ] ], [ [ 1154, 24, 154 ], [ 154, 24, 951 ] ], [ [ 1154, 25, 990 ], [ 990, 24, 951 ] ] ]
[ [ [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doravirine" ], [ "Doravirine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Donepezil" ], [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mirtazapine" ], [ "Mirtazapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lurasidone" ], [ "Lurasidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lomitapide" ], [ "Lomitapide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ] ]
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib Pasireotide may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Palbociclib Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Pasireotide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Pasireotide may lead to a major life threatening interaction when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Pasireotide may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
DB00400
DB12010
353
214
[ "DDInter843", "DDInter785" ]
Griseofulvin
Fostamatinib
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Moderate
1
[ [ [ 353, 24, 214 ] ], [ [ 353, 24, 976 ], [ 976, 24, 214 ] ], [ [ 353, 24, 861 ], [ 861, 63, 214 ] ], [ [ 353, 25, 879 ], [ 879, 24, 214 ] ], [ [ 353, 63, 79 ], [ 79, 24, 214 ] ], [ [ 353, 64, 566 ], [ 566, 24, 214 ] ], [ [ 353, 23, 271 ], [ 271, 24, 214 ] ], [ [ 353, 62, 168 ], [ 168, 24, 214 ] ], [ [ 353, 63, 215 ], [ 215, 25, 214 ] ], [ [ 353, 24, 915 ], [ 915, 25, 214 ] ] ]
[ [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ripretinib" ], [ "Ripretinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lumateperone" ], [ "Lumateperone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sorafenib" ], [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may lead to a major life threatening interaction when taken with {v}", "Levonorgestrel" ], [ "Levonorgestrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mirabegron" ], [ "Mirabegron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Indinavir" ], [ "Indinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Fostamatinib" ] ], [ [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ], [ "Atazanavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Fostamatinib" ] ] ]
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may lead to a major life threatening interaction when taken with Lumateperone and Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may lead to a major life threatening interaction when taken with Levonorgestrel and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may lead to a major life threatening interaction when taken with Fostamatinib Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Fostamatinib
DB00321
DB00682
21
126
[ "DDInter78", "DDInter1951" ]
Amitriptyline
Warfarin
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Moderate
1
[ [ [ 21, 24, 126 ] ], [ [ 21, 40, 11244 ], [ 11244, 40, 126 ] ], [ [ 21, 1, 11305 ], [ 11305, 40, 126 ] ], [ [ 21, 35, 1376 ], [ 1376, 40, 126 ] ], [ [ 21, 6, 3486 ], [ 3486, 45, 126 ] ], [ [ 21, 25, 1053 ], [ 1053, 62, 126 ] ], [ [ 21, 24, 477 ], [ 477, 62, 126 ] ], [ [ 21, 24, 79 ], [ 79, 24, 126 ] ], [ [ 21, 24, 1017 ], [ 1017, 63, 126 ] ], [ [ 21, 25, 478 ], [ 478, 63, 126 ] ] ]
[ [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound)", "Pheniramine" ], [ "Pheniramine", "{u} (Compound) resembles {v} (Compound)", "Warfarin" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound)", "Phenindione" ], [ "Phenindione", "{u} (Compound) resembles {v} (Compound)", "Warfarin" ] ], [ [ "Amitriptyline", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} (Compound) resembles {v} (Compound)", "Warfarin" ] ], [ [ "Amitriptyline", "{u} (Compound) binds {v} (Gene)", "CYP2C8" ], [ "CYP2C8", "{u} (Gene) is bound by {v} (Compound)", "Warfarin" ] ], [ [ "Amitriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cilostazol" ], [ "Cilostazol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sorafenib" ], [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Amitriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ] ]
Amitriptyline (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Warfarin (Compound) Amitriptyline (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Warfarin (Compound) Amitriptyline (Compound) resembles Diphenhydramine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound) Amitriptyline (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound) Amitriptyline may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Warfarin Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin Amitriptyline may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
DB08901
DB09276
1,468
381
[ "DDInter1492", "DDInter1682" ]
Ponatinib
Sodium aurothiomalate
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Moderate
1
[ [ [ 1468, 24, 381 ] ], [ [ 1468, 63, 1683 ], [ 1683, 24, 381 ] ], [ [ 1468, 64, 1047 ], [ 1047, 24, 381 ] ], [ [ 1468, 25, 375 ], [ 375, 24, 381 ] ], [ [ 1468, 24, 1480 ], [ 1480, 63, 381 ] ], [ [ 1468, 63, 1487 ], [ 1487, 25, 381 ] ], [ [ 1468, 64, 1064 ], [ 1064, 25, 381 ] ], [ [ 1468, 63, 1683 ], [ 1683, 63, 491 ], [ 491, 24, 381 ] ], [ [ 1468, 63, 491 ], [ 491, 24, 1683 ], [ 1683, 24, 381 ] ], [ [ 1468, 64, 1047 ], [ 1047, 63, 491 ], [ 491, 24, 381 ] ] ]
[ [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Trastuzumab emtansine" ], [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ], [ [ "Ponatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Trastuzumab emtansine" ], [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium aurothiomalate" ] ] ]
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Sodium aurothiomalate Ponatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sodium aurothiomalate Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate Ponatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
DB00792
DB01075
832
1,376
[ "DDInter1878", "DDInter569" ]
Tripelennamine
Diphenhydramine
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Moderate
1
[ [ [ 832, 24, 1376 ] ], [ [ 832, 40, 649 ], [ 649, 63, 1376 ] ], [ [ 832, 40, 526 ], [ 526, 40, 1376 ] ], [ [ 832, 63, 128 ], [ 128, 24, 1376 ] ], [ [ 832, 1, 11786 ], [ 11786, 40, 1376 ] ], [ [ 832, 40, 508 ], [ 508, 24, 1376 ] ], [ [ 832, 40, 11233 ], [ 11233, 1, 1376 ] ], [ [ 832, 24, 1443 ], [ 1443, 24, 1376 ] ], [ [ 832, 35, 1405 ], [ 1405, 24, 1376 ] ], [ [ 832, 40, 888 ], [ 888, 25, 1376 ] ] ]
[ [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Tropicamide" ], [ "Tropicamide", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Captodiame" ], [ "Captodiame", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Promazine" ], [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Dimetacrine" ], [ "Dimetacrine", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimenhydrinate" ], [ "Dimenhydrinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyclobenzaprine" ], [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Tamoxifen" ], [ "Tamoxifen", "{u} may lead to a major life threatening interaction when taken with {v}", "Diphenhydramine" ] ] ]
Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Tripelennamine (Compound) resembles Tropicamide (Compound) and Tropicamide (Compound) resembles Diphenhydramine (Compound) Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Tripelennamine (Compound) resembles Captodiame (Compound) and Captodiame (Compound) resembles Diphenhydramine (Compound) Tripelennamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Tripelennamine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Diphenhydramine (Compound) Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate and Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Tripelennamine (Compound) resembles Cyclobenzaprine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Tripelennamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
DB00196
DB05812
600
1,374
[ "DDInter743", "DDInter8" ]
Fluconazole
Abiraterone
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Moderate
1
[ [ [ 600, 24, 1374 ] ], [ [ 600, 24, 1561 ], [ 1561, 1, 1374 ] ], [ [ 600, 6, 8374 ], [ 8374, 45, 1374 ] ], [ [ 600, 21, 29113 ], [ 29113, 60, 1374 ] ], [ [ 600, 23, 466 ], [ 466, 62, 1374 ] ], [ [ 600, 23, 112 ], [ 112, 23, 1374 ] ], [ [ 600, 25, 1135 ], [ 1135, 62, 1374 ] ], [ [ 600, 24, 798 ], [ 798, 23, 1374 ] ], [ [ 600, 24, 68 ], [ 68, 62, 1374 ] ], [ [ 600, 24, 1028 ], [ 1028, 24, 1374 ] ] ]
[ [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Testosterone" ], [ "Testosterone", "{u} (Compound) resembles {v} (Compound)", "Abiraterone" ] ], [ [ "Fluconazole", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Abiraterone" ] ], [ [ "Fluconazole", "{u} (Compound) causes {v} (Side Effect)", "Hypokalaemia" ], [ "Hypokalaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nelfinavir" ], [ "Nelfinavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ], [ "Troleandomycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Abiraterone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Torasemide" ], [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abiraterone" ] ] ]
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound) Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound) Fluconazole (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound) Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Abiraterone Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone Fluconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Abiraterone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Abiraterone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
DB00722
DB06792
743
1,606
[ "DDInter1079", "DDInter1023" ]
Lisinopril
Lanthanum carbonate
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for treating high phosphate levels, mainly found in patients with chronic kidney disease. Lanthanum should be taken with meals and binds to phosphate in the diet, preventing phosphate absorption in the intestine.
Moderate
1
[ [ [ 743, 24, 1606 ] ], [ [ 743, 1, 610 ], [ 610, 24, 1606 ] ], [ [ 743, 40, 1638 ], [ 1638, 24, 1606 ] ], [ [ 743, 1, 610 ], [ 610, 1, 664 ], [ 664, 24, 1606 ] ], [ [ 743, 1, 1058 ], [ 1058, 40, 610 ], [ 610, 24, 1606 ] ], [ [ 743, 40, 1638 ], [ 1638, 1, 610 ], [ 610, 24, 1606 ] ], [ [ 743, 1, 954 ], [ 954, 63, 1545 ], [ 1545, 24, 1606 ] ], [ [ 743, 1, 954 ], [ 954, 24, 1487 ], [ 1487, 24, 1606 ] ], [ [ 743, 1, 954 ], [ 954, 24, 428 ], [ 428, 63, 1606 ] ], [ [ 743, 35, 1144 ], [ 1144, 63, 610 ], [ 610, 24, 1606 ] ] ]
[ [ [ "Lisinopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Trandolapril" ], [ "Trandolapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Enalapril" ], [ "Enalapril", "{u} (Compound) resembles {v} (Compound)", "Perindopril" ], [ "Perindopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Moexipril" ], [ "Moexipril", "{u} (Compound) resembles {v} (Compound)", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Trandolapril" ], [ "Trandolapril", "{u} (Compound) resembles {v} (Compound)", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Quinapril" ], [ "Quinapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxytetracycline" ], [ "Oxytetracycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Quinapril" ], [ "Quinapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound)", "Quinapril" ], [ "Quinapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ], [ [ "Lisinopril", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ] ] ]
Lisinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate Lisinopril (Compound) resembles Nateglinide (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
DB00446
DB01592
597
1,596
[ "DDInter351", "DDInter975" ]
Chloramphenicol
Iron
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
Moderate
1
[ [ [ 597, 24, 1596 ] ], [ [ 597, 21, 28666 ], [ 28666, 60, 1596 ] ], [ [ 597, 24, 1096 ], [ 1096, 23, 1596 ] ], [ [ 597, 24, 1191 ], [ 1191, 24, 1596 ] ], [ [ 597, 24, 174 ], [ 174, 63, 1596 ] ], [ [ 597, 25, 1292 ], [ 1292, 63, 1596 ] ], [ [ 597, 24, 627 ], [ 627, 64, 1596 ] ], [ [ 597, 23, 1459 ], [ 1459, 64, 1596 ] ], [ [ 597, 21, 28666 ], [ 28666, 60, 1096 ], [ 1096, 23, 1596 ] ], [ [ 597, 24, 1096 ], [ 1096, 21, 29243 ], [ 29243, 60, 1596 ] ] ]
[ [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} (Compound) causes {v} (Side Effect)", "Nervous system disorder" ], [ "Nervous system disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levodopa" ], [ "Levodopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferric derisomaltose" ], [ "Ferric derisomaltose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bictegravir" ], [ "Bictegravir", "{u} may lead to a major life threatening interaction when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dolutegravir" ], [ "Dolutegravir", "{u} may lead to a major life threatening interaction when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} (Compound) causes {v} (Side Effect)", "Nervous system disorder" ], [ "Nervous system disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Iron" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} (Compound) causes {v} (Side Effect)", "Wheezing" ], [ "Wheezing", "{u} (Side Effect) is caused by {v} (Compound)", "Iron" ] ] ]
Chloramphenicol (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Iron (Compound) Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Iron Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ferric derisomaltose and Ferric derisomaltose may cause a moderate interaction that could exacerbate diseases when taken with Iron Chloramphenicol may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Iron Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may lead to a major life threatening interaction when taken with Iron Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Iron Chloramphenicol (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Iron (Compound)
DB00322
DB00685
141
1,299
[ "DDInter742", "DDInter1887" ]
Floxuridine
Trovafloxacin
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Minor
0
[ [ [ 141, 23, 1299 ] ], [ [ 141, 23, 872 ], [ 872, 40, 1299 ] ], [ [ 141, 18, 3199 ], [ 3199, 45, 1299 ] ], [ [ 141, 21, 28852 ], [ 28852, 60, 1299 ] ], [ [ 141, 24, 995 ], [ 995, 62, 1299 ] ], [ [ 141, 63, 377 ], [ 377, 23, 1299 ] ], [ [ 141, 24, 322 ], [ 322, 23, 1299 ] ], [ [ 141, 35, 1238 ], [ 1238, 23, 1299 ] ], [ [ 141, 24, 663 ], [ 663, 24, 1299 ] ], [ [ 141, 24, 384 ], [ 384, 63, 1299 ] ] ]
[ [ [ "Floxuridine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gemifloxacin" ], [ "Gemifloxacin", "{u} (Compound) resembles {v} (Compound)", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} (Compound) downregulates {v} (Gene)", "TOP2A" ], [ "TOP2A", "{u} (Gene) is bound by {v} (Compound)", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} (Compound) causes {v} (Side Effect)", "Leukopenia" ], [ "Leukopenia", "{u} (Side Effect) is caused by {v} (Compound)", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyurea" ], [ "Hydroxyurea", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mitomycin" ], [ "Mitomycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentostatin" ], [ "Pentostatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trovafloxacin" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trovafloxacin" ] ] ]
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound) Floxuridine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Trovafloxacin (Compound) Floxuridine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Trovafloxacin (Compound) Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin Floxuridine (Compound) resembles Pentostatin (Compound) and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin
DB01186
DB06691
107
849
[ "DDInter1430", "DDInter1155" ]
Pergolide
Mepyramine
Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Moderate
1
[ [ [ 107, 24, 849 ] ], [ [ 107, 63, 1594 ], [ 1594, 24, 849 ] ], [ [ 107, 6, 12523 ], [ 12523, 45, 849 ] ], [ [ 107, 24, 407 ], [ 407, 63, 849 ] ], [ [ 107, 24, 830 ], [ 830, 24, 849 ] ], [ [ 107, 63, 662 ], [ 662, 35, 849 ] ], [ [ 107, 63, 1594 ], [ 1594, 1, 11775 ], [ 11775, 40, 849 ] ], [ [ 107, 6, 12523 ], [ 12523, 45, 23 ], [ 23, 40, 849 ] ], [ [ 107, 63, 770 ], [ 770, 63, 1594 ], [ 1594, 24, 849 ] ], [ [ 107, 24, 407 ], [ 407, 63, 1594 ], [ 1594, 24, 849 ] ] ]
[ [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenindamine" ], [ "Phenindamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} (Compound) resembles {v} (Compound)", "Chloropyramine" ], [ "Chloropyramine", "{u} (Compound) resembles {v} (Compound)", "Mepyramine" ] ], [ [ "Pergolide", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Rosiglitazone" ], [ "Rosiglitazone", "{u} (Compound) resembles {v} (Compound)", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Pergolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ] ]
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Pergolide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound) Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) Pergolide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Mepyramine (Compound) Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
DB00734
DB01261
1,664
170
[ "DDInter1605", "DDInter1679" ]
Risperidone
Sitagliptin
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Moderate
1
[ [ [ 1664, 24, 170 ] ], [ [ 1664, 6, 8374 ], [ 8374, 45, 170 ] ], [ [ 1664, 21, 28850 ], [ 28850, 60, 170 ] ], [ [ 1664, 24, 52 ], [ 52, 62, 170 ] ], [ [ 1664, 24, 1616 ], [ 1616, 63, 170 ] ], [ [ 1664, 1, 924 ], [ 924, 63, 170 ] ], [ [ 1664, 25, 1154 ], [ 1154, 63, 170 ] ], [ [ 1664, 63, 1179 ], [ 1179, 24, 170 ] ], [ [ 1664, 24, 1674 ], [ 1674, 24, 170 ] ], [ [ 1664, 6, 8374 ], [ 8374, 48, 11640 ], [ 11640, 44, 170 ] ] ]
[ [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Sitagliptin" ] ], [ [ "Risperidone", "{u} (Compound) causes {v} (Side Effect)", "Back pain" ], [ "Back pain", "{u} (Side Effect) is caused by {v} (Compound)", "Sitagliptin" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dulaglutide" ], [ "Dulaglutide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ], [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} (Compound) resembles {v} (Compound)", "Iloperidone" ], [ "Iloperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin lispro" ], [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sitagliptin" ] ], [ [ "Risperidone", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is associated with {v} (Disease)", "type 2 diabetes mellitus" ], [ "type 2 diabetes mellitus", "{u} (Disease) is treated by {v} (Compound)", "Sitagliptin" ] ] ]
Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound) Risperidone (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound) Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin Risperidone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
DB00006
DB01191
942
1,039
[ "DDInter217", "DDInter518" ]
Bivalirudin
Dexfenfluramine
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Moderate
1
[ [ [ 942, 24, 1039 ] ], [ [ 942, 25, 1046 ], [ 1046, 63, 1039 ] ], [ [ 942, 24, 578 ], [ 578, 63, 1039 ] ], [ [ 942, 24, 935 ], [ 935, 24, 1039 ] ], [ [ 942, 25, 702 ], [ 702, 24, 1039 ] ], [ [ 942, 64, 1578 ], [ 1578, 24, 1039 ] ], [ [ 942, 24, 222 ], [ 222, 25, 1039 ] ], [ [ 942, 24, 1427 ], [ 1427, 64, 1039 ] ], [ [ 942, 25, 39 ], [ 39, 64, 1039 ] ], [ [ 942, 25, 1046 ], [ 1046, 25, 578 ], [ 578, 63, 1039 ] ] ]
[ [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ketoprofen" ], [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lepirudin" ], [ "Lepirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vortioxetine" ], [ "Vortioxetine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ], [ "Panobinostat", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexfenfluramine" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ] ]
Bivalirudin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Bivalirudin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may lead to a major life threatening interaction when taken with Dexfenfluramine Bivalirudin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Dexfenfluramine Bivalirudin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
DB05316
DB12130
749
1,017
[ "DDInter1467", "DDInter1094" ]
Pimavanserin
Lorlatinib
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Moderate
1
[ [ [ 749, 24, 1017 ] ], [ [ 749, 63, 1101 ], [ 1101, 23, 1017 ] ], [ [ 749, 24, 1491 ], [ 1491, 24, 1017 ] ], [ [ 749, 63, 888 ], [ 888, 24, 1017 ] ], [ [ 749, 64, 11 ], [ 11, 24, 1017 ] ], [ [ 749, 25, 1154 ], [ 1154, 24, 1017 ] ], [ [ 749, 24, 971 ], [ 971, 63, 1017 ] ], [ [ 749, 25, 877 ], [ 877, 63, 1017 ] ], [ [ 749, 63, 1220 ], [ 1220, 25, 1017 ] ], [ [ 749, 24, 927 ], [ 927, 25, 1017 ] ] ]
[ [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may lead to a major life threatening interaction when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Pimavanserin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ] ]
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib
DB00398
DB01035
79
1,401
[ "DDInter1702", "DDInter1524" ]
Sorafenib
Procainamide
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
A derivative of procaine with less CNS action.
Major
2
[ [ [ 79, 25, 1401 ] ], [ [ 79, 6, 12523 ], [ 12523, 45, 1401 ] ], [ [ 79, 21, 28658 ], [ 28658, 60, 1401 ] ], [ [ 79, 23, 112 ], [ 112, 23, 1401 ] ], [ [ 79, 24, 770 ], [ 770, 63, 1401 ] ], [ [ 79, 24, 480 ], [ 480, 24, 1401 ] ], [ [ 79, 25, 982 ], [ 982, 64, 1401 ] ], [ [ 79, 24, 888 ], [ 888, 25, 1401 ] ], [ [ 79, 24, 1228 ], [ 1228, 64, 1401 ] ], [ [ 79, 63, 618 ], [ 618, 25, 1401 ] ] ]
[ [ [ "Sorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Procainamide" ] ], [ [ "Sorafenib", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ], [ "Formoterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may lead to a major life threatening interaction when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ], [ "Lenvatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Procainamide" ] ], [ [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abarelix" ], [ "Abarelix", "{u} may lead to a major life threatening interaction when taken with {v}", "Procainamide" ] ] ]
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound) Sorafenib (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound) Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Procainamide Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procainamide Sorafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Procainamide Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Procainamide Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may lead to a major life threatening interaction when taken with Procainamide Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may lead to a major life threatening interaction when taken with Procainamide
DB00762
DB01165
613
1,539
[ "DDInter973", "DDInter1325" ]
Irinotecan
Ofloxacin
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Minor
0
[ [ [ 613, 23, 1539 ] ], [ [ 613, 62, 1467 ], [ 1467, 1, 1539 ] ], [ [ 613, 23, 945 ], [ 945, 40, 1539 ] ], [ [ 613, 23, 739 ], [ 739, 1, 1539 ] ], [ [ 613, 6, 5912 ], [ 5912, 45, 1539 ] ], [ [ 613, 18, 3199 ], [ 3199, 45, 1539 ] ], [ [ 613, 7, 17450 ], [ 17450, 46, 1539 ] ], [ [ 613, 18, 3186 ], [ 3186, 57, 1539 ] ], [ [ 613, 21, 29090 ], [ 29090, 60, 1539 ] ], [ [ 613, 24, 869 ], [ 869, 23, 1539 ] ] ]
[ [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Enoxacin" ], [ "Enoxacin", "{u} (Compound) resembles {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sparfloxacin" ], [ "Sparfloxacin", "{u} (Compound) resembles {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lomefloxacin" ], [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) binds {v} (Gene)", "ABCC2" ], [ "ABCC2", "{u} (Gene) is bound by {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) downregulates {v} (Gene)", "TOP2A" ], [ "TOP2A", "{u} (Gene) is bound by {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) upregulates {v} (Gene)", "FKBP14" ], [ "FKBP14", "{u} (Gene) is upregulated by {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) downregulates {v} (Gene)", "RB1" ], [ "RB1", "{u} (Gene) is downregulated by {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) causes {v} (Side Effect)", "Weight decreased" ], [ "Weight decreased", "{u} (Side Effect) is caused by {v} (Compound)", "Ofloxacin" ] ], [ [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ], [ "Topotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ofloxacin" ] ] ]
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound) Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound) Irinotecan may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Ofloxacin (Compound) Irinotecan (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Ofloxacin (Compound) Irinotecan (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Ofloxacin (Compound) Irinotecan (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Ofloxacin (Compound) Irinotecan (Compound) downregulates RB1 (Gene) and RB1 (Gene) is downregulated by Ofloxacin (Compound) Irinotecan (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Ofloxacin (Compound) Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
DB00938
DB01087
455
1,520
[ "DDInter1635", "DDInter1520" ]
Salmeterol
Primaquine
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Moderate
1
[ [ [ 455, 24, 1520 ] ], [ [ 455, 24, 1487 ], [ 1487, 64, 1520 ] ], [ [ 455, 6, 8374 ], [ 8374, 45, 1520 ] ], [ [ 455, 21, 28722 ], [ 28722, 60, 1520 ] ], [ [ 455, 63, 508 ], [ 508, 24, 1520 ] ], [ [ 455, 24, 1342 ], [ 1342, 63, 1520 ] ], [ [ 455, 24, 739 ], [ 739, 24, 1520 ] ], [ [ 455, 64, 1622 ], [ 1622, 24, 1520 ] ], [ [ 455, 25, 1056 ], [ 1056, 24, 1520 ] ], [ [ 455, 25, 609 ], [ 609, 63, 1520 ] ] ]
[ [ [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Primaquine" ] ], [ [ "Salmeterol", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Primaquine" ] ], [ [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promazine" ], [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Romidepsin" ], [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lomefloxacin" ], [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Voriconazole" ], [ "Voriconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Telithromycin" ], [ "Telithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ], [ [ "Salmeterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Primaquine" ] ] ]
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Primaquine (Compound) Salmeterol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Primaquine (Compound) Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine Salmeterol may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Primaquine Salmeterol may lead to a major life threatening interaction when taken with Telithromycin and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine Salmeterol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
DB06616
DB09078
594
1,228
[ "DDInter224", "DDInter1036" ]
Bosutinib
Lenvatinib
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Moderate
1
[ [ [ 594, 24, 1228 ] ], [ [ 594, 62, 112 ], [ 112, 23, 1228 ] ], [ [ 594, 64, 463 ], [ 463, 23, 1228 ] ], [ [ 594, 64, 609 ], [ 609, 24, 1228 ] ], [ [ 594, 63, 1084 ], [ 1084, 24, 1228 ] ], [ [ 594, 25, 384 ], [ 384, 24, 1228 ] ], [ [ 594, 24, 603 ], [ 603, 63, 1228 ] ], [ [ 594, 24, 1616 ], [ 1616, 24, 1228 ] ], [ [ 594, 25, 913 ], [ 913, 63, 1228 ] ], [ [ 594, 75, 1069 ], [ 1069, 25, 1228 ] ] ]
[ [ [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Rifampicin" ], [ "Rifampicin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lofexidine" ], [ "Lofexidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium citrate" ], [ "Magnesium citrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ], [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ] ], [ [ "Bosutinib", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Vandetanib" ], [ "Vandetanib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lenvatinib" ] ] ]
Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib Bosutinib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib Bosutinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib Bosutinib (Compound) resembles Vandetanib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
DB00912
DB12887
473
1,598
[ "DDInter1581", "DDInter1750" ]
Repaglinide
Tazemetostat
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Moderate
1
[ [ [ 473, 24, 1598 ] ], [ [ 473, 63, 168 ], [ 168, 23, 1598 ] ], [ [ 473, 24, 1039 ], [ 1039, 24, 1598 ] ], [ [ 473, 63, 752 ], [ 752, 24, 1598 ] ], [ [ 473, 24, 466 ], [ 466, 63, 1598 ] ], [ [ 473, 24, 609 ], [ 609, 25, 1598 ] ], [ [ 473, 63, 1419 ], [ 1419, 25, 1598 ] ], [ [ 473, 63, 168 ], [ 168, 23, 985 ], [ 985, 24, 1598 ] ], [ [ 473, 24, 1039 ], [ 1039, 64, 888 ], [ 888, 24, 1598 ] ], [ [ 473, 24, 1476 ], [ 1476, 62, 168 ], [ 168, 23, 1598 ] ] ]
[ [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tazemetostat" ] ] ]
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
DB00912
DB12267
473
1,476
[ "DDInter1581", "DDInter233" ]
Repaglinide
Brigatinib
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Moderate
1
[ [ [ 473, 24, 1476 ] ], [ [ 473, 24, 1612 ], [ 1612, 23, 1476 ] ], [ [ 473, 25, 1206 ], [ 1206, 23, 1476 ] ], [ [ 473, 63, 168 ], [ 168, 23, 1476 ] ], [ [ 473, 63, 629 ], [ 629, 24, 1476 ] ], [ [ 473, 24, 800 ], [ 800, 24, 1476 ] ], [ [ 473, 24, 1385 ], [ 1385, 63, 1476 ] ], [ [ 473, 64, 839 ], [ 839, 24, 1476 ] ], [ [ 473, 25, 255 ], [ 255, 24, 1476 ] ], [ [ 473, 63, 566 ], [ 566, 25, 1476 ] ] ]
[ [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostemsavir" ], [ "Fostemsavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may lead to a major life threatening interaction when taken with {v}", "Gemfibrozil" ], [ "Gemfibrozil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ], [ "Duvelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ], [ "Semaglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may lead to a major life threatening interaction when taken with {v}", "Delafloxacin" ], [ "Delafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levonorgestrel" ], [ "Levonorgestrel", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ] ]
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib Repaglinide may lead to a major life threatening interaction when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Repaglinide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Repaglinide may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel may lead to a major life threatening interaction when taken with Brigatinib
DB12130
DB13179
1,017
68
[ "DDInter1094", "DDInter1882" ]
Lorlatinib
Troleandomycin
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
A macrolide antibiotic that is similar to erythromycin.
Major
2
[ [ [ 1017, 25, 68 ] ], [ [ 1017, 63, 1601 ], [ 1601, 23, 68 ] ], [ [ 1017, 62, 1101 ], [ 1101, 23, 68 ] ], [ [ 1017, 25, 466 ], [ 466, 23, 68 ] ], [ [ 1017, 63, 309 ], [ 309, 24, 68 ] ], [ [ 1017, 64, 1220 ], [ 1220, 24, 68 ] ], [ [ 1017, 24, 1619 ], [ 1619, 24, 68 ] ], [ [ 1017, 63, 1618 ], [ 1618, 25, 68 ] ], [ [ 1017, 24, 971 ], [ 971, 25, 68 ] ], [ [ 1017, 64, 594 ], [ 594, 25, 68 ] ] ]
[ [ [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loratadine" ], [ "Loratadine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixabepilone" ], [ "Ixabepilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ], [ [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ] ]
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Troleandomycin Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Lorlatinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin Lorlatinib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Troleandomycin
DB00951
DB06589
1,072
1,250
[ "DDInter986", "DDInter1400" ]
Isoniazid
Pazopanib
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Moderate
1
[ [ [ 1072, 24, 1250 ] ], [ [ 1072, 6, 7950 ], [ 7950, 45, 1250 ] ], [ [ 1072, 21, 28658 ], [ 28658, 60, 1250 ] ], [ [ 1072, 63, 112 ], [ 112, 23, 1250 ] ], [ [ 1072, 23, 1135 ], [ 1135, 62, 1250 ] ], [ [ 1072, 24, 14 ], [ 14, 24, 1250 ] ], [ [ 1072, 63, 663 ], [ 663, 24, 1250 ] ], [ [ 1072, 24, 1491 ], [ 1491, 63, 1250 ] ], [ [ 1072, 23, 1220 ], [ 1220, 24, 1250 ] ], [ [ 1072, 23, 115 ], [ 115, 63, 1250 ] ] ]
[ [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} (Compound) binds {v} (Gene)", "CYP1A2" ], [ "CYP1A2", "{u} (Gene) is bound by {v} (Compound)", "Pazopanib" ] ], [ [ "Isoniazid", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rosuvastatin" ], [ "Rosuvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Isoniazid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Aluminum hydroxide" ], [ "Aluminum hydroxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ] ]
Isoniazid (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound) Isoniazid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound) Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib Isoniazid may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Pazopanib Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Isoniazid may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Isoniazid may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
DB00687
DB04855
870
540
[ "DDInter747", "DDInter602" ]
Fludrocortisone
Dronedarone
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.
Major
2
[ [ [ 870, 25, 540 ] ], [ [ 870, 64, 228 ], [ 228, 40, 540 ] ], [ [ 870, 25, 33 ], [ 33, 40, 540 ] ], [ [ 870, 21, 28778 ], [ 28778, 60, 540 ] ], [ [ 870, 24, 28 ], [ 28, 63, 540 ] ], [ [ 870, 24, 473 ], [ 473, 24, 540 ] ], [ [ 870, 63, 663 ], [ 663, 24, 540 ] ], [ [ 870, 1, 1220 ], [ 1220, 24, 540 ] ], [ [ 870, 23, 480 ], [ 480, 24, 540 ] ], [ [ 870, 25, 976 ], [ 976, 63, 540 ] ] ]
[ [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Dofetilide" ], [ "Dofetilide", "{u} (Compound) resembles {v} (Compound)", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Amiodarone" ], [ "Amiodarone", "{u} (Compound) resembles {v} (Compound)", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} (Compound) causes {v} (Side Effect)", "Anaphylactic shock" ], [ "Anaphylactic shock", "{u} (Side Effect) is caused by {v} (Compound)", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bisacodyl" ], [ "Bisacodyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Formoterol" ], [ "Formoterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ], [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronedarone" ] ] ]
Fludrocortisone may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound) Fludrocortisone may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound) Fludrocortisone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Dronedarone (Compound) Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone Fludrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
DB00176
DB01132
529
1,130
[ "DDInter770", "DDInter1472" ]
Fluvoxamine
Pioglitazone
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.
Moderate
1
[ [ [ 529, 24, 1130 ] ], [ [ 529, 6, 12523 ], [ 12523, 45, 1130 ] ], [ [ 529, 21, 28661 ], [ 28661, 60, 1130 ] ], [ [ 529, 24, 303 ], [ 303, 23, 1130 ] ], [ [ 529, 24, 11 ], [ 11, 24, 1130 ] ], [ [ 529, 25, 1039 ], [ 1039, 63, 1130 ] ], [ [ 529, 24, 214 ], [ 214, 63, 1130 ] ], [ [ 529, 63, 1685 ], [ 1685, 24, 1130 ] ], [ [ 529, 25, 1466 ], [ 1466, 24, 1130 ] ], [ [ 529, 25, 1347 ], [ 1347, 25, 1130 ] ] ]
[ [ [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} (Compound) causes {v} (Side Effect)", "Acute coronary syndrome" ], [ "Acute coronary syndrome", "{u} (Side Effect) is caused by {v} (Compound)", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Medroxyprogesterone acetate" ], [ "Medroxyprogesterone acetate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin human" ], [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ], [ "Phenylpropanolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ] ], [ [ "Fluvoxamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may lead to a major life threatening interaction when taken with {v}", "Pioglitazone" ] ] ]
Fluvoxamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound) Fluvoxamine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound) Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Pioglitazone Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone Fluvoxamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone Fluvoxamine may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Pioglitazone
DB00703
DB00759
997
1,620
[ "DDInter1167", "DDInter1783" ]
Methazolamide
Tetracycline
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.
Minor
0
[ [ [ 997, 23, 1620 ] ], [ [ 997, 62, 1572 ], [ 1572, 40, 1620 ] ], [ [ 997, 23, 1669 ], [ 1669, 40, 1620 ] ], [ [ 997, 6, 10612 ], [ 10612, 45, 1620 ] ], [ [ 997, 40, 471 ], [ 471, 62, 1620 ] ], [ [ 997, 24, 1254 ], [ 1254, 63, 1620 ] ], [ [ 997, 63, 176 ], [ 176, 24, 1620 ] ], [ [ 997, 62, 1572 ], [ 1572, 1, 11377 ], [ 11377, 40, 1620 ] ], [ [ 997, 62, 1545 ], [ 1545, 40, 1572 ], [ 1572, 40, 1620 ] ], [ [ 997, 23, 1669 ], [ 1669, 40, 1572 ], [ 1572, 40, 1620 ] ] ]
[ [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Demeclocycline" ], [ "Demeclocycline", "{u} (Compound) resembles {v} (Compound)", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Minocycline" ], [ "Minocycline", "{u} (Compound) resembles {v} (Compound)", "Tetracycline" ] ], [ [ "Methazolamide", "{u} (Compound) binds {v} (Gene)", "SLC22A6" ], [ "SLC22A6", "{u} (Gene) is bound by {v} (Compound)", "Tetracycline" ] ], [ [ "Methazolamide", "{u} (Compound) resembles {v} (Compound)", "Acetazolamide" ], [ "Acetazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ], [ "Insulin glulisine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Demeclocycline" ], [ "Demeclocycline", "{u} (Compound) resembles {v} (Compound)", "Methacycline" ], [ "Methacycline", "{u} (Compound) resembles {v} (Compound)", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Oxytetracycline" ], [ "Oxytetracycline", "{u} (Compound) resembles {v} (Compound)", "Demeclocycline" ], [ "Demeclocycline", "{u} (Compound) resembles {v} (Compound)", "Tetracycline" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Minocycline" ], [ "Minocycline", "{u} (Compound) resembles {v} (Compound)", "Demeclocycline" ], [ "Demeclocycline", "{u} (Compound) resembles {v} (Compound)", "Tetracycline" ] ] ]
Methazolamide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound) Methazolamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline (Compound) resembles Tetracycline (Compound) Methazolamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Tetracycline (Compound) Methazolamide (Compound) resembles Acetazolamide (Compound) and Acetazolamide may cause a minor interaction that can limit clinical effects when taken with Tetracycline Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline Methazolamide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Methacycline (Compound) and Methacycline (Compound) resembles Tetracycline (Compound) Methazolamide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound) Methazolamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound)
DB00215
DB00916
1,230
112
[ "DDInter388", "DDInter1202" ]
Citalopram
Metronidazole
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
Minor
0
[ [ [ 1230, 23, 112 ] ], [ [ 1230, 6, 8374 ], [ 8374, 45, 112 ] ], [ [ 1230, 21, 29612 ], [ 29612, 60, 112 ] ], [ [ 1230, 64, 618 ], [ 618, 23, 112 ] ], [ [ 1230, 25, 51 ], [ 51, 23, 112 ] ], [ [ 1230, 25, 1616 ], [ 1616, 62, 112 ] ], [ [ 1230, 24, 477 ], [ 477, 62, 112 ] ], [ [ 1230, 1, 318 ], [ 318, 62, 112 ] ], [ [ 1230, 24, 1144 ], [ 1144, 24, 112 ] ], [ [ 1230, 23, 522 ], [ 522, 24, 112 ] ] ]
[ [ [ "Citalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Metronidazole" ] ], [ [ "Citalopram", "{u} (Compound) causes {v} (Side Effect)", "Loss of libido" ], [ "Loss of libido", "{u} (Side Effect) is caused by {v} (Compound)", "Metronidazole" ] ], [ [ "Citalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Abarelix" ], [ "Abarelix", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Daunorubicin" ], [ "Daunorubicin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ], [ "Histrelin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cilostazol" ], [ "Cilostazol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} (Compound) resembles {v} (Compound)", "Escitalopram" ], [ "Escitalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ] ], [ [ "Citalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zafirlukast" ], [ "Zafirlukast", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ] ] ]
Citalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) Citalopram (Compound) causes Loss of libido (Side Effect) and Loss of libido (Side Effect) is caused by Metronidazole (Compound) Citalopram may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole Citalopram may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole Citalopram may lead to a major life threatening interaction when taken with Histrelin and Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole Citalopram (Compound) resembles Escitalopram (Compound) and Es Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole Citalopram may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
DB00911
DB06448
458
171
[ "DDInter1811", "DDInter1087" ]
Tinidazole
Lonafarnib
A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]
Moderate
1
[ [ [ 458, 24, 171 ] ], [ [ 458, 63, 63 ], [ 63, 24, 171 ] ], [ [ 458, 40, 112 ], [ 112, 24, 171 ] ], [ [ 458, 24, 310 ], [ 310, 63, 171 ] ], [ [ 458, 24, 309 ], [ 309, 24, 171 ] ], [ [ 458, 24, 129 ], [ 129, 64, 171 ] ], [ [ 458, 62, 752 ], [ 752, 25, 171 ] ], [ [ 458, 24, 392 ], [ 392, 25, 171 ] ], [ [ 458, 63, 467 ], [ 467, 25, 171 ] ], [ [ 458, 63, 63 ], [ 63, 24, 112 ], [ 112, 24, 171 ] ] ]
[ [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teniposide" ], [ "Teniposide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} (Compound) resembles {v} (Compound)", "Metronidazole" ], [ "Metronidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixabepilone" ], [ "Ixabepilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lonafarnib" ] ], [ [ "Tinidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teniposide" ], [ "Teniposide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lonafarnib" ] ] ]
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib Tinidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Lonafarnib Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
DB00030
DB00703
1,685
997
[ "DDInter934", "DDInter1167" ]
Insulin human
Methazolamide
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Moderate
1
[ [ [ 1685, 24, 997 ] ], [ [ 1685, 24, 471 ], [ 471, 1, 997 ] ], [ [ 1685, 24, 1572 ], [ 1572, 23, 997 ] ], [ [ 1685, 24, 1669 ], [ 1669, 62, 997 ] ], [ [ 1685, 24, 1130 ], [ 1130, 63, 997 ] ], [ [ 1685, 24, 175 ], [ 175, 24, 997 ] ], [ [ 1685, 24, 1645 ], [ 1645, 25, 997 ] ], [ [ 1685, 24, 1479 ], [ 1479, 64, 997 ] ], [ [ 1685, 24, 471 ], [ 471, 5, 11595 ], [ 11595, 44, 997 ] ], [ [ 1685, 24, 1572 ], [ 1572, 23, 471 ], [ 471, 1, 997 ] ] ]
[ [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetazolamide" ], [ "Acetazolamide", "{u} (Compound) resembles {v} (Compound)", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Demeclocycline" ], [ "Demeclocycline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Minocycline" ], [ "Minocycline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ], [ "Pioglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metformin" ], [ "Metformin", "{u} may lead to a major life threatening interaction when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetazolamide" ], [ "Acetazolamide", "{u} (Compound) treats {v} (Disease)", "glaucoma" ], [ "glaucoma", "{u} (Disease) is treated by {v} (Compound)", "Methazolamide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Demeclocycline" ], [ "Demeclocycline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetazolamide" ], [ "Acetazolamide", "{u} (Compound) resembles {v} (Compound)", "Methazolamide" ] ] ]
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound) Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life threatening interaction when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Methazolamide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Methazolamide (Compound) Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
DB00341
DB01075
1,242
1,376
[ "DDInter343", "DDInter569" ]
Cetirizine
Diphenhydramine
Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Moderate
1
[ [ [ 1242, 24, 1376 ] ], [ [ 1242, 24, 649 ], [ 649, 63, 1376 ] ], [ [ 1242, 40, 11314 ], [ 11314, 1, 1376 ] ], [ [ 1242, 24, 128 ], [ 128, 24, 1376 ] ], [ [ 1242, 40, 11397 ], [ 11397, 40, 1376 ] ], [ [ 1242, 63, 357 ], [ 357, 24, 1376 ] ], [ [ 1242, 5, 11598 ], [ 11598, 44, 1376 ] ], [ [ 1242, 6, 10104 ], [ 10104, 45, 1376 ] ], [ [ 1242, 54, 19190 ], [ 19190, 15, 1376 ] ], [ [ 1242, 21, 28921 ], [ 28921, 60, 1376 ] ] ]
[ [ [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) resembles {v} (Compound)", "Eprazinone" ], [ "Eprazinone", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) resembles {v} (Compound)", "Cinnarizine" ], [ "Cinnarizine", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benzatropine" ], [ "Benzatropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) treats {v} (Disease)", "allergic rhinitis" ], [ "allergic rhinitis", "{u} (Disease) is treated by {v} (Compound)", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) binds {v} (Gene)", "HRH1" ], [ "HRH1", "{u} (Gene) is bound by {v} (Compound)", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) is included by {v} (Pharmacologic Class)", "Histamine H1 Receptor Antagonists" ], [ "Histamine H1 Receptor Antagonists", "{u} (Pharmacologic Class) includes {v} (Compound)", "Diphenhydramine" ] ], [ [ "Cetirizine", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Diphenhydramine" ] ] ]
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Cetirizine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Diphenhydramine (Compound) Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Cetirizine (Compound) resembles Cinnarizine (Compound) and Cinnarizine (Compound) resembles Diphenhydramine (Compound) Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Cetirizine (Compound) treats allergic rhinitis (Disease) and allergic rhinitis (Disease) is treated by Diphenhydramine (Compound) Cetirizine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Diphenhydramine (Compound) Cetirizine (Compound) is included by Histamine H1 Receptor Antagonists (Pharmacologic Class) and Histamine H1 Receptor Antagonists (Pharmacologic Class) includes Diphenhydramine (Compound) Cetirizine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
DB00323
DB00514
1,062
506
[ "DDInter1829", "DDInter527" ]
Tolcapone
Dextromethorphan
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]
Moderate
1
[ [ [ 1062, 24, 506 ] ], [ [ 1062, 6, 6017 ], [ 6017, 45, 506 ] ], [ [ 1062, 21, 28810 ], [ 28810, 60, 506 ] ], [ [ 1062, 24, 13 ], [ 13, 24, 506 ] ], [ [ 1062, 24, 717 ], [ 717, 63, 506 ] ], [ [ 1062, 1, 1533 ], [ 1533, 24, 506 ] ], [ [ 1062, 63, 701 ], [ 701, 24, 506 ] ], [ [ 1062, 25, 1629 ], [ 1629, 64, 506 ] ], [ [ 1062, 6, 6017 ], [ 6017, 45, 890 ], [ 890, 40, 506 ] ], [ [ 1062, 21, 28810 ], [ 28810, 60, 197 ], [ 197, 40, 506 ] ] ]
[ [ [ "Tolcapone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} (Compound) causes {v} (Side Effect)", "Gastrointestinal pain" ], [ "Gastrointestinal pain", "{u} (Side Effect) is caused by {v} (Compound)", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimethobenzamide" ], [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} (Compound) resembles {v} (Compound)", "Entacapone" ], [ "Entacapone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} may lead to a major life threatening interaction when taken with {v}", "Methylene blue" ], [ "Methylene blue", "{u} may lead to a major life threatening interaction when taken with {v}", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Mestranol" ], [ "Mestranol", "{u} (Compound) resembles {v} (Compound)", "Dextromethorphan" ] ], [ [ "Tolcapone", "{u} (Compound) causes {v} (Side Effect)", "Gastrointestinal pain" ], [ "Gastrointestinal pain", "{u} (Side Effect) is caused by {v} (Compound)", "Levorphanol" ], [ "Levorphanol", "{u} (Compound) resembles {v} (Compound)", "Dextromethorphan" ] ] ]
Tolcapone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dextromethorphan (Compound) Tolcapone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Dextromethorphan (Compound) Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan Tolcapone (Compound) resembles Entacapone (Compound) and Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan Tolcapone may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Dextromethorphan Tolcapone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Mestranol (Compound) and Mestranol (Compound) resembles Dextromethorphan (Compound) Tolcapone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Levorphanol (Compound) and Levorphanol (Compound) resembles Dextromethorphan (Compound)
DB08885
DB10316
363
334
[ "DDInter33", "DDInter1248" ]
Aflibercept
Mumps virus strain B level jeryl lynn live antigen
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain.[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
Major
2
[ [ [ 363, 25, 334 ] ], [ [ 363, 64, 1057 ], [ 1057, 25, 334 ] ], [ [ 363, 25, 976 ], [ 976, 25, 334 ] ], [ [ 363, 63, 599 ], [ 599, 25, 334 ] ], [ [ 363, 25, 1259 ], [ 1259, 64, 334 ] ], [ [ 363, 24, 713 ], [ 713, 25, 334 ] ], [ [ 363, 24, 270 ], [ 270, 64, 334 ] ], [ [ 363, 64, 1057 ], [ 1057, 25, 1042 ], [ 1042, 24, 334 ] ], [ [ 363, 64, 908 ], [ 908, 64, 1042 ], [ 1042, 24, 334 ] ], [ [ 363, 25, 976 ], [ 976, 64, 1042 ], [ 1042, 24, 334 ] ] ]
[ [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alemtuzumab" ], [ "Alemtuzumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ], [ "Dimethyl fumarate", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Golimumab" ], [ "Golimumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ], [ [ "Aflibercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mumps virus strain B level jeryl lynn live antigen" ] ] ]
Aflibercept may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen Aflibercept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
DB08865
DB09143
1,593
313
[ "DDInter448", "DDInter1701" ]
Crizotinib
Sonidegib
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Major
2
[ [ [ 1593, 25, 313 ] ], [ [ 1593, 63, 1559 ], [ 1559, 23, 313 ] ], [ [ 1593, 64, 478 ], [ 478, 24, 313 ] ], [ [ 1593, 25, 1375 ], [ 1375, 63, 313 ] ], [ [ 1593, 63, 578 ], [ 578, 24, 313 ] ], [ [ 1593, 24, 951 ], [ 951, 24, 313 ] ], [ [ 1593, 24, 1320 ], [ 1320, 63, 313 ] ], [ [ 1593, 25, 1313 ], [ 1313, 24, 313 ] ], [ [ 1593, 24, 800 ], [ 800, 64, 313 ] ], [ [ 1593, 63, 1249 ], [ 1249, 25, 313 ] ] ]
[ [ [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Famotidine" ], [ "Famotidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lefamulin" ], [ "Lefamulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ], [ "Palbociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Suvorexant" ], [ "Suvorexant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ], [ "Duvelisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Sonidegib" ] ], [ [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nafcillin" ], [ "Nafcillin", "{u} may lead to a major life threatening interaction when taken with {v}", "Sonidegib" ] ] ]
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib Crizotinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may lead to a major life threatening interaction when taken with Suvorexant and Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may lead to a major life threatening interaction when taken with Sonidegib Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may lead to a major life threatening interaction when taken with Sonidegib
DB00529
DB00816
789
1,674
[ "DDInter779", "DDInter1346" ]
Foscarnet
Orciprenaline
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Moderate
1
[ [ [ 789, 24, 1674 ] ], [ [ 789, 21, 28921 ], [ 28921, 60, 1674 ] ], [ [ 789, 63, 251 ], [ 251, 23, 1674 ] ], [ [ 789, 24, 891 ], [ 891, 62, 1674 ] ], [ [ 789, 24, 167 ], [ 167, 23, 1674 ] ], [ [ 789, 63, 618 ], [ 618, 24, 1674 ] ], [ [ 789, 24, 484 ], [ 484, 63, 1674 ] ], [ [ 789, 24, 888 ], [ 888, 24, 1674 ] ], [ [ 789, 25, 485 ], [ 485, 24, 1674 ] ], [ [ 789, 25, 1487 ], [ 1487, 63, 1674 ] ] ]
[ [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ], [ "Hydrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abarelix" ], [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may lead to a major life threatening interaction when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Foscarnet", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ] ]
Foscarnet (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound) Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Foscarnet may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Foscarnet may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
DB00352
DB08916
482
26
[ "DDInter1814", "DDInter32" ]
Tioguanine
Afatinib
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim .
Moderate
1
[ [ [ 482, 24, 26 ] ], [ [ 482, 63, 883 ], [ 883, 40, 26 ] ], [ [ 482, 21, 28868 ], [ 28868, 60, 26 ] ], [ [ 482, 24, 651 ], [ 651, 24, 26 ] ], [ [ 482, 24, 1320 ], [ 1320, 63, 26 ] ], [ [ 482, 63, 912 ], [ 912, 24, 26 ] ], [ [ 482, 25, 990 ], [ 990, 25, 26 ] ], [ [ 482, 63, 883 ], [ 883, 6, 4973 ], [ 4973, 45, 26 ] ], [ [ 482, 21, 28868 ], [ 28868, 60, 883 ], [ 883, 40, 26 ] ], [ [ 482, 24, 651 ], [ 651, 63, 883 ], [ 883, 40, 26 ] ] ]
[ [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) resembles {v} (Compound)", "Afatinib" ] ], [ [ "Tioguanine", "{u} (Compound) causes {v} (Side Effect)", "Stomatitis" ], [ "Stomatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fosphenytoin" ], [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Afatinib" ] ], [ [ "Tioguanine", "{u} may lead to a major life threatening interaction when taken with {v}", "Lomitapide" ], [ "Lomitapide", "{u} may lead to a major life threatening interaction when taken with {v}", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Afatinib" ] ], [ [ "Tioguanine", "{u} (Compound) causes {v} (Side Effect)", "Stomatitis" ], [ "Stomatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) resembles {v} (Compound)", "Afatinib" ] ], [ [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fosphenytoin" ], [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) resembles {v} (Compound)", "Afatinib" ] ] ]
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound) Tioguanine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Afatinib (Compound) Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Afatinib Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Afatinib Tioguanine may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Afatinib Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound) Tioguanine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound) Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)